FREE patent keyword monitoring and additional FREE benefits. /images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
Fresh Patents freshpatentsnav7_icons (5K)
browse patent apps by agents browse patent apps by inventors browse patent apps by industry browse patents by location monitor patent applications
    



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2008 | Recent  |  08: Dec | Nov | Oct | Sp | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 07: D | N | O | S | A | J | J | M | A | M | F | J |  | 06: 12 | 11 | 10 | 09 | 8 | 7 | 6 | 5 | 4 | Dec | Nov |  | 2010 | 2009 |

    SEARCH:      Monitor Keywords | rss Custom RSS

Drug, bio-affecting and body treating compositions January USPTO class listing 01/08

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/31/2008 > patent applications in patent subcategories. USPTO class listing

20080026983 - Compositions and methods for alleviating joint pain and improving joint flexibility: A Composition and method for administering a nutritional supplement to an individual, e.g., a human or animal, are provided for the alleviation of joint pain, long-lasting relief from joint pain, improvement of joint functioning as well as help to restore joint flexibility through a reduction of inflammation. The nutritional supplement... Agent: Kenyon & Kenyon LLP

20080026982 - Mutant apobec3g molecules for inhibiting replication of hiv: Provided herein are novel APOBEC3G polypeptides having an amino acid substitution at position 129, e.g., P129D in which the polypeptide is capable of resisting proteosomal degradation induced by HIV-Vif. Also provided are isolated nucleic acids encoding the APOBEC3G polypeptides, recombinant vectors comprising the nucleic acids, recombinant host cells comprising the... Agent: Kaliko & Yeager, L.L.C.

20080026981 - Pharmaceutical compositions: A process for micronization of pharmaceutically active agents.... Agent: Novartis Corporate Intellectual Property

20080026980 - Use of agents derived from ceacam1 for the treatment of inflammatory diseases: The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid... Agent: Cooper & Dunham, LLP

20080026990 - 18-membered nitrobenzyl- and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites and a process for their preparation: The invention relates to cyclic depsipeptides, especially 18-membered cyclohexadepsipeptides of general formula (I) and the salts thereof, wherein R1 represents nitrobenzyl or R′R″N-benzyl—wherein R′ and R″ independently represent hydrogen, optionally substituted C1-C4-alkyl, formyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxycarbonyl, or hydroxy-C1-C2-alkyl-sulfonyl-C1-C2-alkyl, or, together with the nitrogen atom to which they are bound, R′ and... Agent: Bayer Healthcare LLC

20080026995 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20080026999 - Two-component bacillus lantibiotic and methods for producing and using the same: The present invention relates to two-component lantibiotics isolated from Bacillus sp. Methods for producing said lantibiotics are provided, wherein dehydration and cyclization of the peptides is carried out by two substrate-specific modifying enzymes. Given the antimicrobial activity of the instant lantibiotics, methods for preventing or treating bacterial infections are also... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20080026992 - Tyrosine phosphorylation of cdk inhibitor proteins of the cip/kip family: The present invention is directed to tyrosine phosphorylated forms of Cip/Kip proteins including p27Kip1, fragments of these forms and antibodies thereto. The invention is further related to non-phosphorylatable forms of Cip/Kip proteins, or fragments thereof. Further embodiments are diagnostic or therapeutic uses of the disclosed compounds, in particular uses in... Agent: Wilson Sonsini Goodrich & Rosati

20080027005 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: This application discloses compositions and methods for treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on multimeric peptides.... Agent: Goodwin Procter LLP

20080027006 - Compositions and methods for modification and prevention of sars coronavirus infectivity: The invention relates to diseases of coronaviruses, particularly severe acute respiratory syndrome (SARS). Compositions and methods in connection with peptide-based compounds are described relating to inhibition or prevention of coronavirus activity including that of SARS coronavirus and the ability of its S protein to achieve fusion with and entry into... Agent: Greenlee Winner And Sullivan P C

20080027008 - Antitumorigenic drug combination: Compositions comprising drugs having cooperative activity and methods of treatment using the combinations are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20080027009 - Surfactant preparation having reduced enzyme damaging: A method of protecting skin enzymes from the harmful effects of a cosmetic cleansing preparation which comprises water and one or more anionic surfactants. The method comprises using a cleansing preparation which has a pH value of from 4 to 7 and an SCTE (Stratum Comeum Tryptic Enzyme) value, determined... Agent: Greenblum & Bernstein, P.L.C

20080027014 - Novel sglt inhibitors: m

20080027016 - Cancer treatment application of genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome of the affected area with a “younger” one will hopefully... Agent: John M Pavelchik

20080027018 - Electrotransfer of nucleic acid into tissue cells: n

20080027015 - Methods and materials for modulating enac-beta: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of ENaC-beta. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding ENaC-beta.... Agent: Fish & Richardson P.C.

20080027017 - Spinal and nerve application of genomic replacement therapy: Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully aid in the treatment... Agent: John M Pavelchik

20080027026 - Composition for the treatment of inflammatory conditions: A novel treatment for topical inflammatory conditions such as acne, eczema, shingles, insect bites and hives is provided, consisting of the application of a pharmaceutical cream or ointment which incorporates hydroxypropyl methylcellulose acetate succinate (“HPMCAS”) in a micronized form and which preferably contains one or more thickeners, a bio-adhesive agent... Agent: Gottlieb Rackman & Reisman PC

20080027028 - Ketopyrroles useful as ligands in organic iridium compositions: wherein R2 is independently at each occurrence a deuterium atom, a halogen, a nitro group, an amino group, a C3-C40 aromatic radical, a C1-C50 aliphatic radical, or a C3-C40 cyclcoaliphatic radical; “a” is an integer from 0 to 3; and X1 and X2 are independently at each occurrence a bromine... Agent: General Electric Company Global Research

20080026985 - Control of gene expression: A method of suppressing the expression of a selected gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a DNA binding portion which binds to a site at or associated with the selected gene which site is present in a plant or animal... Agent: Nikolai & Mersereau, P.A.

20080026984 - Methods for treating inflammatory disease by administering aldehydes and derivatives thereof: A method is disclosed for treating inflammatory disease in an animal in need thereof by administering to the animal a pharmaceutical composition containing an anti-inflammatory effective amount of an organic aldehyde compound or a derivative thereof in a pharmaceutically acceptable vehicle.... Agent: Wolf Greenfield & Sacks, P.C.

20080026986 - Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling: CD8+ regulatory T (Treg) cells and γδ Treg cells profoundly suppress host immune responses and thus protect against autoimmune disease while restricting desired immune responses such as antitumor immunity. Synthetic phosphorothioate-protected, guanosine-containing oligonucleotides can directly reverse the suppressive activity of Treg cells without involving dendritic cells. This effect appears to... Agent: Fulbright & Jaworski, LLP

20080026987 - Use of liver-selective glucokinase activators: The present invention provides a method of normalizing blood glucose levels in mammals utilizing liver-selective glucokinase activators. The present invention also provides a method of increasing liver metabolism and decreasing apoptosis independent of glucose normalization or hyperglycemic conditions.... Agent: Novo Nordisk, Inc. Patent Department

20080026988 - Compositions and methods for human immunodeficiency virus vaccination: The present invention relates to methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response to human immunodeficiency virus (HIV) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising HIV or antigenic... Agent: Medlen & Carroll, LLP

20080026989 - Human ependymin: The present invention relates to a novel human Ependymin protein which is a member of the ependymin family. In particular, isolated nucleic acid molecules are provided encoding the human Ependymin protein. Ependymin polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080026991 - Compositions containing quaternary ammonium compounds: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at... Agent: Young & Thompson

20080027000 - Apo-a-i regulation of t-cell signaling: The invention provides AFTI polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing AFTI polypeptides. Also provided are methods for the treatment, diagnosis, amelioration, or prevention of diseases with AFTI polypeptides, particularly IL-1 mediated diseases, TNF-α mediated... Agent: Fulbright & Jaworski L.L.P.

20080027002 - Compositions and methods for targeting cancer-specific transcription complexes: The invention provides molecules that target cancer-specific transcription complexes (CSTC), compositions and kits comprising CSTC-targeting molecules, and methods of using CSTC-targeting molecules for the treatment) detection and monitoring of cancer.... Agent: Karen S. Canady Canady & Lortz LLP

20080026998 - Human kunitz-type inhibitor with enhanced antifibrinolytic activity: A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2).... Agent: Mueting, Raasch & Gebhardt, P.A.

20080026997 - Medicament for the treatment of fungal infections particularly aspergillosis: The combination of pentraxin PTX3 with antifungal agents is described for the treatment of fungal infections and particularly for infections caused by Aspergillus fumigatus. Thanks to the synergistic effect of the two drugs, the combination allows the administration of suboptimal doses of antifungal agent.... Agent: Nixon & Vanderhye, PC

20080026993 - Modified growth hormones: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... Agent: Fish & Richardson, PC

20080026994 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20080027001 - Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same: The present invention provides novel isolated and purified polynucleotides and polypeptides related to functional motifs of the Nogo receptor 1 (NgR1) (e.g., the binding pocket on the side surface of NgR1, functional motifs comprising the amino acid sequence of FRG, etc.) and use of peptides mimicking these functional motifs as... Agent: Fitzpatrick Cella Harper & Scinto

20080026996 - Selective vpac2 receptor reptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080027003 - Peptides useful for treating gnrh associated diseases: A peptide comprising at least one hydrophobic moiety attached to an amino acid sequence capable of binding a GnRH receptor, the amino acid sequence being at least 11 amino acids in length. Also provided are methods of using such peptides for the treatment of GnRH-associated diseases.... Agent: Martin D. Moynihan Prtsi

20080027004 - Phosphorylated cop1 molecules and uses thereof: The invention provides COP1 molecules and modulators of COP1 activity and methods of using them, including diagnostic and therapeutic uses thereof. Such molecules can be useful for detecting DNA damage and modulating the response to DNA damage and p53 activity in subjects. The invention also provides reagents and kits for... Agent: Heller Ehrman LLP

20080027007 - Control of radiation injury: The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides... Agent: Trask Britt

20080027010 - Treatment of refractory cancers using na+/k+-atpase inhibitors: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027012 - Bridged carbamate macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20080027011 - Homogeneous paste and gel formulations: This invention provides for a pharmaceutical or veterinary paste or gel formulation which may comprise an effective amount of a therapeutic agent; optionally an absorbent or a viscosity modifier; optionally a hydrophilic carrier, a colorant, stabilizer, surfactant, or preservative and optionally an antioxidant, solvent, flavoring, buffering system or thickener and... Agent: Judy Jarecki-black, Ph.d.,j.d.

20080027013 - Antibacterial treatment of osteoarthritis: The present invention relates to use of an antibacterial agent in the manufacture of a medicament for the treatment of osteoarthritis, more particularly for the treatment of a bacterial infection which is responsible for osteoarthritis. Also described are methods for the diagnosis of osteoarthritis through the detection of certain bacteria... Agent: Needle & Rosenberg, P.C.

20080027020 - Human neuropeptide receptor: Human neuropeptide receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080027019 - Oligonucleotide compositions and methods for the modulation of the expression of b7 protein: Compositions and methods for the treatment of asthma with oligonucleotides which specifically hybridize with nucleic acids encoding B7 proteins.... Agent: Knobbe, Martens, Olson & Bear, LLP

20080027021 - Use of cpg oligodeoxynucleotides to induce angiogenesis: This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This... Agent: Klarquist Sparkman, LLP

20080027022 - Method to treat gastric lesions: The present invention provides a therapeutic method for treating gastric lesions, including administration to a patient in need thereof of an effective amount of an A2A adenosine receptor agonist. The A2A adenosine receptor agonist can be a compound of formula (I) as disclosed herein. The invention further provides a therapeutic... Agent: Schwegman, Lundberg & Woessner, P.A.

20080027023 - Antiproliferative compositions comprising aryl substituted xylopyranoside derivatives: Novel xylose based glycoside compounds that have xylose linked O-, S- or C-glycosidically to an aglycone containing several aromatic rings, and compositions that comprise the novel xylose based glycosides and non-xylose-based anti-tumor agents, pharmaceuticals or dietary supplements. The compounds or compositions are administered to treat proliferative diseases, including various forms... Agent: Young & Thompson

20080027024 - Dietary supplement and methods of use: One aspect of the invention provides dietary fiber compositions comprising effective amounts of glucomannan, xanthan gum, and alginate to produce a desired viscosity. The invention also provides food products comprising an effective amount of a dietary fiber composition. In other aspects, the invention provides methods for preparing a dietary fiber... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080027025 - Protection from and treatment of prion protein infection: The disclosure for the first time provides an understanding of the mechanism of prion protein infection: prion proteins contain a cationic protein transduction domain (PTD) that interacts with the cell surface such that it induces macropinocytosis and enters the cytoplasm.... Agent: Buchanan, Ingersoll & Rooney LLP

20080027027 - Lactosucrose high content saccharide, its preparation and uses: The present invention solves above objects by providing a lactosucrose high content saccharide comprising 70% or more of lactosucrose and less than 3% of the total amount of 1-kestose and fructosyl lactosucrose, on a saccharide composition basis; a process for producing the lactosucrose high content saccharide, comprising the steps of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080027029 - Cold menthol receptor-1 antagonists: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or... Agent: Philip S. Johnson Johnson & Johnson

20080027030 - Pharmaceutical compositions comprising amifostine and related compounds: The present invention is directed to pharmaceutical compositions comprising amifostine or a related compound and a compound which may be selected from the group consisting of an anesthetic, a corticosteroid, an antihistamine and an anti-inflammatory. The present invention is also directed to methods of treating or protecting tissue of a... Agent: Jones Day

20080027031 - Retinoids and related compounds for the treatment of neuroinflammatory conditions, diseases and disorders: The proliferation and activation of microglia is emerging as an important etiologic factor and target for therapeutic intervention in several CNS diseases, including Alzheimer's disease and multiple sclerosis. Here, we have discovered that retinoic acids dramatically inhibit microglial proliferation in an in vivo model including the widely-used animal model of... Agent: Morgan, Lewis & Bockius, LLP

20080027032 - Combinations comprising cox-2 inhibitors and aspirin: A pharmaceutical composition is provided for treatment of conditions in mammals which are responsive to COX-2 inhibition which comprises in combination a COX-2 inhibitor and low-dose aspirin for simultaneous, sequential or separate use... Agent: Novartis Corporate Intellectual Property

20080027033 - Method and composition for treatment of cutaneous lesions: A method of treatment or prophylaxis of a cutaneous lesion in an animal the method comprising topically applying to an area of skin of the animal a composition comprising: one or more metal chelators; one or more transforming growth factor modulators; and one or more dermal penetration enhancers.... Agent: Foley And Lardner LLP Suite 500

20080027034 - Ciclesonide and syk inhibitor combination and method of use thereof: The invention relates to pharmaceutical formulations containing combinations of ciclesonide and a syk inhibitor and the use of such pharmaceutical compositions in medicine, in particular in the prophylaxis and treatment of respiratory disease.... Agent: Nath & Associates PLLC

20080027035 - Dpp-iv inhibitors: e

20080027036 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune... Agent: Goodwin Procter LLP Patent Administrator

20080027038 - N-acylated lipophilic amino acid derivatives: Compounds of structural formula (I) where A is a lipophilic group including an aliphatic bridging group, B is a lipophilic group, D is a group having at least one amino or substituted amino group and R is hydrogen, alkyl or cycloalkyl, and pharmaceutically acceptable salts and individual isomers thereof, which... Agent: Nixon & Vanderhye, PC

20080027037 - Cyclic compounds: wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted),... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080027039 - Method for treating a motor neuron disease: According to the present invention, there is provided a method for treating a motor neuron disease, comprising the step of administering a therapeutically effective amount of a compound having serotonin receptor antagonist activity or its pharmacologically acceptable salt or their solvate optionally together with a pharmaceutically acceptable carrier to a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080027040 - Oxazolidinone-quinolone hybrid antibiotics: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:... Agent: Edwards Angell Palmer & Dodge LLP

20080027041 - Pyridizinone derivatives: e

20080027042 - Novel aminopyridine derivatives having aurora a selective inhibitory action: wherein m1 and m2 are 1, 2, or 3; n1 and n2 are 0 or 1; i is an integer of any of 1 to m1; j is an integer of 1 to m2; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rai and Rai′ is... Agent: Merck And Co., Inc

20080027043 - Preparation of antimicrobial formulations using 7-oxa-2-thia-1,5-diazabicyclo[3.3.1]nonane-2,2-dione: Use of 7-oxa-2-thia-1,5-diazabicyclo[3.3.1]nonane-2,2-dione (“cyclotaurolidin”) for the preparation of antimicrobial formulations, in particular antimicrobial solutions for technical or medical purposes and of aqueous lock solutions for catheters and port systems for preventing infections and sepsis of patients.... Agent: Henry M. Feiereisen Henry M. Feiereisen, LLC

20080027044 - Prodrug antibiotic screens: Methods for identifying prodrug activity utilizing screens with microbial mutants, including null and conditional mutants, transiently gene-repressed microbes, and gene-overexpressing microbes, as well as pooled collections of these are provided. Effective prodrug antibiotics differentially kill or inhibit microbes overexpressing prodrug activating genes and allow non-expressing strains to grow and be... Agent: Wilmerhale/boston

20080027045 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents: The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080027046 - Synergistic mixtures of anthranilamide invertebrate pest control agents: and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors,... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20080027047 - Compounds that modulate hsp90 activity and methods for identifying same: The present invention relates to compositions and methods related to inhibitors of Hsp90, including substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080027048 - 2-phenylthiophene derivative: The present invention relates to a 2-phenylthiophene derivative or a salt thereof, wherein the thiophene ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the... Agent: Sughrue-265550

20080027049 - Benzofurans as potassium ion channel modulators: e

20080027050 - Heterocyclic amide compound and use thereof as an mmp-13 inhibitor(amended ex officio): The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen-containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted... Agent: Edwards Angell Palmer & Dodge LLP

20080027052 - Methods for treating cystic kidney disease: The present invention relates to methods for treating or preventing cystic kidney diseases or disorders using calcimimetics and pharmaceutically acceptable salts of these compounds. Various aspects related to treating mammal including humans. Still other aspects related to various formulations including combination formulation that may be used to treat kidney disease... Agent: Sommer Barnard Attorneys,p.c.

20080027051 - Novel heteroaryl substituted benzoxazoles: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027053 - Antimicrobial oxazolidinone prodrugs: This invention includes oxazolidinone prodrug compounds of Formula (I) and Formula (II) as defined herein. The prodrugs are convertible by natural biological processes into an active ingredient possessed of antimicrobial properties useful in treating bacterial infections in mammals.... Agent: Philip S. Johnson Johnson & Johnson

20080027055 - 1-aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080027054 - 4-substituted quinolines as antitumor agents: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament... Agent: Morgan Lewis & Bockius LLP

20080027056 - Substituted heterocyclic ethers and their use in cns disorders: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080027057 - Use of dihydroimidazolones for the treatment of dogs: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1 H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.... Agent: Fulbright & Jaworski, LLP

20080027058 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080027059 - Substituted isoxazolines, pharmaceutical compositions containing same, methods of preparing same, and uses of same: in which A, R1, R2, R3, R4, Z, X, m, n, and p, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted isoxazolines, to methods of preparing said substituted isoxazolines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of... Agent: Millen, White, Zelano & Branigan, P.C.

20080027060 - Dipeptide nitriles: In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080027061 - Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080027062 - 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level: The present invention relates to the area of NO synthase inhibition and, more particularly, relates to novel 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment of a disorder characterized by a disturbed nitric oxide level.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080027063 - Imidazopyrazines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080027064 - Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds... Agent: Fulbright & Jaworski, LLP

20080027065 - Compounds: e

20080027066 - Arylpiperazinyl compounds: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural... Agent: Goodwin Procter LLP Patent Administrator

20080027068 - Heterocyclic compounds and thrombopoietin receptor activators: wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080027067 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080027069 - Quinazoline compounds: The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) Q1X1 wherein Q1 and X1 are as... Agent: Morgan Lewis & Bockius LLP

20080027070 - 2-amino--5-substituted pyrimidine inhibitors: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.... Agent: Dla Piper US LLP

20080027071 - Novel heteroaryl derivatives, their preparation and use: A heteroaryl derivative having the formula (I). The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080027072 - Potentiation of mc4 receptor activity: The present invention provides methods of treating obesity, eating disorders, and sexual dysfunction. The methods comprise administering to a mammalian host suffering from obesity, an eating disorder, or sexual dysfunction an effective dose of a compound of the invention. Also provided are methods of potentiating the effect of an MC4... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027073 - Substituted indanyl sulfonamide compounds, their preparation and use as medicaments: e

20080027074 - 2-(1h-indolysulfanyl)-aryl amine derivatives for use in the treatment of affective disorders, pain, adhd and stress urinary incontinence: The present invention relates to aniline derivatives of the general formula I as the free base or salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20080027075 - Quaternary amino-function chalcones: The present invention provides novel quaternary amino-functional chalcone derivatives and analogues exhibiting interesting antibacterial activity. The compounds have the general formula (Y1)m—Ar1(X1)—C(=O)VAr2(X2)−(Y2)p (I), wherein V designates —CH2—CH2—, —CH═CH— or —C≡C—; Ar1 and Ar2 independently are aryl and heteroaryl; m=0, 1, 2, p=0, 1, 2, m+p>0; each Y1 and Y2 independently... Agent: Edwards Angell Palmer & Dodge LLP

20080027076 - Pyrimidines with tie2 (tek) activity: The invention relates to a compound of the Formula (I); or salt thereof, wherein R1, R2, R3, R4, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and... Agent: Astrazeneca R&d Boston

20080027077 - Novel biaromatic compounds that modulate ppargamma type receptors and cosmetic/pharmaceutical compositions comprised thereof: e

20080027079 - Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity:

20080027078 - 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1h)one derivatives:

20080027080 - Cyclic derivatives as modulators of chemokine receptor activity: This invention relates generally to modulators of chemokine receptor activity having unexpected combination of desirable pharmacological properties. Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases, particularly diabetes, Crohn's disease, atherosclerosis, and multiple... Agent: Louis J. Wille Bristol-myers Squibb Company

20080027081 - Therapeutic compounds: The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2′,3′-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic... Agent: Edwards Angell Palmer & Dodge LLP

20080027082 - Use of adenosine a1 antagonists in radiocontrast media induced nephropathy: Described herein are pharmaceutical combinations comprising a therapeutically effective amount of a first selective adenosine A1 antagonist and a first radiocontrast media. In one embodiment the selective adenosine A1 antagonist comprises 4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-trans-cyclohexanol methanesulfonate and/or (4S)-4-hydroxy-1-(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-L-prolinamide methanesulfonate. Also described are the use of a first selective adenosine A1 antagonist in the... Agent: Mayer Brown LLP

20080027084 - Modulators of chemokine receptor activity crystalline forms and process: s

20080027083 - Modulators of chemokine receptor activity crystalline forms and process:

20080027085 - 2-(pyridin-2-yl)-pyrimidines and their use for controlling harmful fungi: The invention relates to 2-(pyridin-2-yl)-pyrimidine compounds of general formula (I) and their use for controlling pathogenic fungi and as plant protection products that, as an active constituent, contain compounds of this type, whereby: k represents 0, 1, 2, 3; m represents 0, 1, 2, 3, 4 or 5; n represents... Agent: Birch Stewart Kolasch & Birch

20080027086 - Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles: e

20080027087 - Cb1 antagonists and inverse agonists: The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027088 - Imidazole-based hmg-coa reductase inhibitors: The present invention relates to methods of treating atherosclerosis, dyslipidemia, other cardiovascular diseases and related diseases, such as diabetes, using a serine palmitoyltransferase (SPT) inhibitor. The present invention also relates to pharmaceutical compositions and kits that comprise a serine palmitoyltransferase (SPT) inhibitor, optionally with another pharmaceutical agent.... Agent: Pfizer Inc.

20080027089 - Rapamycin derivatives and the uses thereof in the treatment of neurological disorders: e

20080027090 - Tetracyclic indoles as potassium channel modulators:

20080027091 - Soft anticholinergic zwitterions: wherein R1 and R2 are both phenyl or one of R1 and R2 is phenyl and the other is cyclopentyl; and wherein each asterisk marks a chiral center; said compound having the R, S or RS stereoisomeric configuration at each chiral center unless specified otherwise, or being a mixture thereof.... Agent: Buchanan, Ingersoll & Rooney PC

20080027092 - 1-acetic acid-indole, -indazole and -benzimidazole derivatives useful for the treatment of respiratory disorders: The present invention relates to substituted indoles of formula (I) useful as pharmaceutical compounds for treating respiratory disorders.... Agent: Fish & Richardson P.C.

20080027093 - Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20080027094 - Tropane compounds and pharmaceutical compositions comprising the same as an active ingredient: e

20080027095 - Use of 3-substituted-2-(diphenylmethy)-1-azabicyclo[2.2.2]octanes for treating mrg-x1 receptor mediated diseases: The invention encompasses a method for treating a disease or condition mediated by the human MRG-X1 receptor, such as nociception, hyperalgesia, allodynia, pain related to central hypersensitivity conditions, somatic pain, visceral pain, acute pain, chronic pain, post-operative pain, headache, inflammatory pain, neurological pain, musculoskeletal pain, cancer related pain or vascular... Agent: Merck And Co., Inc

20080027096 - Novel pharmaceutical compositions: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for use in the treatment or prophylaxis of condition mediated by an androgen receptor.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20080027098 - Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation: e

20080027097 - Pharmaceutical drug candidates and methods for preparation thereof: The present invention is directed to methods of preparation of sulfonate derivatized compounds, e.g., 3-amino-1-propanesulfonic acid and 1,3-propanedisulfonic acid disodium salt with increased purity, with reduced potential for toxic by-products, and that are pharmaceutically useful, e.g., for the treatment of amyloidosis.... Agent: Lahive & Cockfield, LLP

20080027099 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080027100 - Functionally selective alpha2c adrenoreceptor agonists: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080027102 - Quinolinyl-pyrrolopyrazoles: A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.... Agent: Eli Lilly & Company

20080027101 - Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound: c

20080027103 - Novel crystalline forms 1: The present invention relates to 6-(4-{[(benzylsulfonyl)amino]carbonyl}piperidin-1-yl)-5-cyano-2-methylnicotinic acid isopropyl ester, form II, to a process for preparing such compound, to its utility as P2Y12 inhibitor and as anti-thrombotic agent etc, its use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing it.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027104 - Novel crystalline forms 2: The present invention relates to 6-(4-{[(benzylsulfonyl)amino]carbonyl}piperidin-1-yl)-5-cyano-2-methylnicotinic acid ethyl ester, form I and II, to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080027105 - Dosing regimen of flavopiridol for treating cancer`: A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080027106 - Methods of treating psychosis and schizphrenia based on polymorphisms in the cntf gene: This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.... Agent: Novartis Corporate Intellectual Property

20080027107 - Antharquinone compounds as anti cancer compounds: Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, —NHR0N (Rs)2 in which R° is a C1l12 alkanediyl and each R5 is H or optionally substituted C14 alkyl, and... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080027108 - Therapeutic substituted lactams: t

20080027109 - Cetp activity inhibitors: wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted... Agent: Leydig Voit & Mayer, Ltd

20080027110 - Indolyl-3-glyoxylic acid derivatives having antitumor action: and to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080027111 - Treatment and prevention of cardiovascular disease using mast cell stabilizers: The present invention is directed to methods of treating or preventing the development of cardiovascular disease by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing cardiovascular disease.... Agent: Law Office Of Michael A. Sanzo, LLC

20080027112 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080027113 - Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits... Agent: Jones Day

20080027114 - Active agent combinations with insecticidal and acaricidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, cyclic ketoenols or other acaricidally active compounds and, secondly, further insecticidally active compounds from the group of the anthranilamides, which combinations are highly suitable for controlling animal pests, such as insects and unwanted acarids.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080027115 - Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof: The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinducer agonists and antagonists, as well as methods for regulating the activity of an autoinducer... Agent: Nixon Peabody LLP - Patent Group

20080027116 - Pharmaceutical composition for treating spinocerebellar ataxia: e

20080027117 - Antifungal azole derivatives having a fluorovinyl moiety and process for the preparation thereof: An azole derivative of formula (I) having a fluorovinyl moiety or a pharmaceutically acceptable salt thereof is superior to the conventional antifungal drugs in antifungal activity against a wide spectrum of pathogenic fungi, and has advantageously low toxicity.... Agent: Anderson, Kill & Olick, P.C.

20080027118 - Prodrugs of mitotic kinesin inhibitors: The present invention relates to prodrugs of dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080027119 - Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders: Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat acute pain, chronic pain, and symptoms associated with neuropathic disorders.... Agent: Black Lowe & Graham, PLLC

20080027120 - Ketorolac tromethamine compositions for treating or preventing ocular pain: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.... Agent: Allergan, Inc.

20080027122 - Indole derivatives: m

20080027121 - Novel pyrone-indole derivatives and process for their preparation: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080027123 - (+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione:methods of using and compositions thereof: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the... Agent: Jones Day

20080027124 - 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase i: as inhibitors of human casein kinase Iε, and methods of using said compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II)... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080027125 - Fluvastatin sodium novel forms and preparation thereof: Provided are a novel solid states of fluvastatin sodium and processes for preparation thereof.... Agent: Kenyon & Kenyon LLP

20080027126 - Pyrrolidin-2-one derivatives for use as dp1 receptor agonists: The present invention is directed to compounds that may be used as agonists of prostaglandin receptors. More specifically, the specification describes methods and compositions for making and using DP1 receptor agonists that are pyrrolidin-2-one derivatives.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080027127 - Trans pyrrolidinyl derivates and their pharmaceutical use: R1, R2 or R3 are hydrogen or a carboxy or amino protecting group; R4 to R8 represent hydrogen or an alkyl radical; R9 represents a (R10)n(—R11)m group wherein R10 is —CO—, —CS—, —O—, —S—, —SO—, —SO2—, —COO—, —CONRa—, —N(Ra)CO—, —CSNRa—, —N(Ra)CS—, —N(Ra)—, Rb, aryl, and R11 is a polar group,... Agent: Young & Thompson

20080027128 - Duloxetine hcl polymorphs: A crystalline form of duloxetine hydrochloride, pharmaceutical compositions of the crystalline form of duloxetine hydrochloride, and methods of preparing the crystalline form of duloxetine hydrochloride are provided.... Agent: Kenyon & Kenyon LLP

20080027129 - Administration of 3h-1, 2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate for the treatment of canities: At least one compound selected from among 3H-1,2-dithiole-3-thione, anethole dithiolethione, sulforaphane, phenethyl isothiocyanate, 6-(methylsulfinyl)hexyl isothiocyanate and allyl isothiocyanate and derivatives and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents... Agent: Buchanan, Ingersoll & Rooney PC

20080027130 - Cytotoxic agents comprising taxanes and their therapeutic use: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent... Agent: Sughrue Mion, Zinn, Macpeak & Seas, PLLC

20080027131 - Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity: The present invention is a method for the treatment of obesity, for promoting weight loss and/or suppressing appetite comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) as herein defined.... Agent: Philip S. Johnson Johnson & Johnson

20080027132 - Materials and methods for treating coagulation disorders: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080027133 - Use of chromen-4-one derivatives: where R1 and R2 may be identical or different and are selected from H, —C(═O)—R7, —C(═O)—OR7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R3 is H or alkyl groups, R4 is H or OR8, R5 and R6 are selected from —H, —OH, alkyl groups, alkenyl... Agent: Millen, White, Zelano & Branigan, P.C.

20080027134 - Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use: e

20080027135 - Methods for identifying chemical modulators of ras superfamily gptase activity: The present invention provides a method of identifying a compound having the ability to modulate the guanine nucleotide exchange cycle of a Ras superfamily GTPase, comprising: a) contacting the compound with a guanine nucleotide exchange factor and a GTPase and obtaining a baseline fluorescence measurement; b) contacting the guanine nucleotide... Agent: Myers Bigel Sibley & Sajovec

20080027136 - Compositions and methods for the treatment of cystic fibrosis: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20080027137 - Synthesis scheme for lacosamide: e

20080027138 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk, Inc. Patent Department

20080027139 - Use of alpha-ketoglutarate and related compounds: The use of at least one member selected from alpha-ketoglutaric acid, glutamine, glutamic acid and pharmaceutically acceptable salts of these acids, amides of alpha-ketoglutaric acid with an amino acid or di- or tripeptide, dipeptides of glutamine and another amino acid, tripeptides of glutamine and other amino acids, dipeptides of glutamine... Agent: Ladas & Parry LLP

20080027140 - Combinations of serotonin reuptake inhibitors and imidazoline i 2 agonists: The present invention relates to combinations of serotonin reuptake inhibitors and imidazoline I2 agonists as separate chemical units or both properties combined in a single molecule and to the use thereof for the preparation of medicaments for the treatment of depression, obsessive-compulsive disorders (OCDs), obsessive-compulsive spectrum disorders (OCSDs) and other... Agent: Millen, White, Zelano & Branigan, P.C.

20080027141 - 1,3-dihydroxyl-9,10-anthraquinone and 3-[(3-amino)-propoxy]- 9,10-anthraquinone derivatives and pharmaceutical compositions comprising the same: Disclosed herein are 1,3-dihydroxyl-9,10-anthraquinone and 3-[(3-amino)-propoxy]-9,10-anthraquinone derivatives, in particular 1,3-dihydroxy-4-prenyl-9,10-anthraquinone and 3-[3-(4-methylpiperazinyl)-propoxy]-9,10-anthraquinone, which are found to have inhibitory activities against several types of human tumor/cancer cells and thus can be used in the manufacture of pharmaceutical compositions for use in the treatment of tumors/cancers.... Agent: Townsend And Townsend And Crew, LLP

20080027142 - System cleaner concentrate: The invention relates to a concentrate for cleaning and disinfection which comprises (i) one or more alkyl alcohol alkoxylates, (ii) one or more formaldehyde donor compounds, (iii) optionally one or more biocidal, in particular fungicidal, active ingredient(s), (iv) optionally one or more glycols and (v) optionally up to 10% by... Agent: Young & Thompson

20080027143 - Chemical formulation for an insecticide: A chemical formulation for an insecticide comprises an active material and a solvent with a viscosity of less than or equal to about 4 centistokes at 25 degrees Celsius, wherein the solvent does not cause damages to a surface. The solvent also has a low gum content to minimize the... Agent: S.c. Johnson & Son, Inc.

20080027144 - Benzonaphthacene glycoside derivative and use thereof: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The... Agent: Birch Stewart Kolasch & Birch

20080027145 - Therapeutic molecules and methods for generating and/or selecting same: The present invention relates generally to therapeutic molecules useful for inducing apoptosis of particular cells such as, but not limited to, cancer cells and methods for generating and/or selecting same. The present invention further provides methods for inducing apoptosis of cells such as cancer cells and pharmaceutical compositions useful for... Agent: The Mccallum Law Firm, P. C.

20080027148 - Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the enzyme peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the enzyme peptides, and methods of identifying... Agent: Celera

20080027146 - Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases: The invention provides genetic markers of periodontal disorders and/or periodontal diseases. The present invention provides methods and compositions to aid in the detection, diagnosis, treatment and monitoring of periodontal disorders and/or periodontal diseases.... Agent: Banner & Witcoff, Ltd.

20080027147 - Novel human transferase family members and uses thereof: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host... Agent: Millennium Pharmaceuticals, Inc.

  
01/24/2008 > patent applications in patent subcategories. USPTO class listing

20080020964 - Test system for the discovery of substances for the promotion of neuraxonal growth: The invention relates to a method for identifying or testing active substances, which influence the growth and survival of nerve cells, wherein a cell is brought into contact with at least one substance and subsequently, within said cell, the mRNA of the β-actin or the β-actin protein alone or together... Agent: Mayer & Williams PC

20080020966 - Novel bacillus thuringiensis gene with coleopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020968 - Novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020967 - Unique novel bacillus thuringiensis gene with lepidopteran activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic... Agent: Pioneer Hi-bred International, Inc.

20080020975 - Galanin receptors and brain injury: There is provided the use of a GALR2-specific agonist in the preparation of a medicament for the prevention or treatment of brain injury, damage or disease, wherein the brain injury or damage is caused by one of: embolic, thrombotic or haemorrhagic stroke; direct or indirect trauma or surgery to the... Agent: Hunton & Williams LLP Intellectual Property Department

20080020981 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080020987 - Processes for preparing pyrazole-o-glycoside derivatives and novel intermediates of said processes: e

20080020991 - Methods of treating, reducing, or preventing autoimmune conditions: The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of... Agent: Clark & Elbing LLP

20080020990 - Oligo double-stranded rna inhibiting the expression of bcl-2 and pharmaceutical composition containing the same: The present invention relates to oligo double-stranded RNAs for use in knockdown of the expression of Bcl-2 protein known as a suppressor for apoptosis, and pharmaceutical compositions containing them. It is known that Bcl-2 protein is over-expressed in diseases such as cancer, and by this over-expression, the growth of cancer... Agent: Darby & Darby P.C.

20080020996 - Esters of capsaicin for treating pain: e

20080021000 - Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species: Mixtures of natural phosphatidylcholine species, natural lysophosphatidylcholine species, phosphatidylserine species, phosphatidylethanolamine species, 1-hydroxy-2-acyl-phosphatidylcholine species, 1-hydroxy-2-acyl-phosphatidylserine molecular species, 1-hydroxy-2-acyl-phosphatidylethanolamine molecular species, 1-O-alkyl-2-hydroxy phosphatidylcholine species, 1-O-alkyl-2-docosaheaxnoyl phosphatidylcholine species 1-O-alkyl-2-docosahexaenoyl phosphatidylserine species, and 1-O-alkyl-2-docosahexaenoyl phosphatidylethanolamine species, Methods using the above disclosed mixtures in mammals to treat various conditions.... Agent: Law Office Of Michael A. Blake

20080020969 - 36 human secreted proteins: The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080020965 - Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants: This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region... Agent: Banner & Witcoff, Ltd.

20080020970 - Somatostatin antagonists: The present invention is directed to a somatostatin antagonist according to formula (I), wherein A1 is an optionally substituted aromatic ax-amino acid; A2 is an optionally substituted aromatic α-amino acid; A3 is Dab, Dap, Lys or Orn; A4 is β-Hydroxyvaline, Ser, Hser, or Thr; A5 is an optionally substituted D-... Agent: Alan F. Feeney, Esq.

20080020971 - Heptanoic acid derivatives as dipeptidyl peptidase inhibitors: The present invention is directed to novel heptanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080020972 - Use of human chorionic gonadotropin orally for the treatment of overweight (obesity) associated with high blood tension, non-insulin-dependent diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy: Human Chorionic Gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be administered orally—sublingual—has been developed with such drug to treat patients suffering from overweight associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. The... Agent: Belluscio, Daniel Oscar

20080020973 - Assays for identification of topoisomerase inhibitors: The instant invention provides a continuous spectroscopic assay for DNA topoisomerase activity. The invention further provides topoisomerase inhibitors and pharmaceutical compositions for the treatment of topoisomerase associated diseases and disorders.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu

20080020974 - Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use... Agent: Biomeasure, Incorporated

20080020976 - Antimicrobially active peptide: An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.... Agent: Knobbe Martens Olson & Bear LLP

20080020978 - Cgrp peptide antagonists and conjugates: Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of... Agent: Amgen Inc.

20080020980 - Magnesium ammonium phosphate cement composition: This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as... Agent: Townsend And Townsend And Crew, LLP

20080020982 - Methods and compositions for treatment of atherosclerosis: The present invention provides methods and compositions for treating subject having atherosclerosis. The invention provides a method comprising administering to a subject having atherosclerosis an effective amount of insulin like growth factor-1 (IGF-1), wherein the administering is effective to treat atherosclerosis in the subject. The invention also provides kits for... Agent: Bozicevic, Field & Francis LLP

20080020979 - Peptides of syndecan-1 for inhibiting angiogenesis: The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis.... Agent: Fulbright & Jaworski L.L.P.

20080020983 - Peptides with antioxidant and antimicrobial properties: One embodiment of the present invention is directed toward methods for inhibiting the oxidation of lipids, proteins, and other compounds. Another embodiment is directed toward methods for treating conditions associated with microbial contamination, colonization, and/or infection.... Agent: Dinsmore & Shohl, LLP

20080020977 - Use of fullerenes to oxidize reduced redox proteins: Disclosed herein is a method of oxidizing a reduced redox protein by contacting an aqueous solution containing the reduced redox protein with a water-soluble substituted fullerene under conditions in which the water-soluble substituted fullerene can oxidize the reduced redox protein. The redox protein can be cytochrome c.... Agent: Williams, Morgan & Amerson

20080020984 - Crystal structure of a receptor-ligand complex and methods of use: The invention relates to the three-dimensional structure of a crystal of an EphB4 receptor complexed with a ligand. The three-dimensional structure of a Receptor-Ligand Complex is disclosed. The receptor-ligand crystal structure, wherein the ligand is an inhibitor molecule, is useful for providing structural information that may be integrated into drug... Agent: Biotactica, LLC

20080020985 - Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof: Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080020986 - Dimeric iap inhibitors: Smac mimetics that inhibit IAPs.... Agent: Pepper Hamilton LLP

20080020988 - Brain cell- or nerve cell-protecting agents comprising medicinal ginseng: The present invention provides medicinal or pharmaceutical compositions and preparations for administration, which are useful as cytoprotective agents and a remedy for neurotrauma, comprising ginseng, its extract, ginseng components, metabolites thereof or salts thereof (for example, red ginseng powder or components thereof). More particularly, the present invention provides medicinal or... Agent: Edwards Angell Palmer & Dodge LLP

20080020989 - Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines: The invention is directed to carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidine compounds, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and pharmaceutical compositions thereof in treating disease states associated with abnormal cell growth, such as cancer.... Agent: Connolly Bove Lodge & Hutz LLP

20080020992 - Multicistronic constructs with sirna to inhibit tumors: Multicistronic short interfering RNA constructs targeting in various combinations a human urokinase-type plasminogen activator receptor (uPAR), human urokinase-type plasminogen activator (uPA), human matrix metalloprotease 9 (MMP-9) and cathepsin B (CB) inhibit tumors.... Agent: Barnes & Thornburg LLP

20080020993 - Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules: Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorder, such as psoriasis, and skin cancer for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by administration of nucleic acid molecules encoding parathyroid hormone (PTI), parathyroid related peptide (PTHrP), or... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080020994 - G proteins in tumor growth and angiogenesis: The invention provides an agent that reduces the expression of Gα12 or Gα13 polypeptide, as well as an agent that enhances G protein Gα12 or Gα13 expression and/or activity. An agent of the invention may be used to decrease or increase G protein Gα12 or Gα13 expression and/or activity thereby... Agent: Schwegman, Lundberg & Woessner, P.A.

20080020995 - Use of cyclodextrin complexes containing lipoic acid: The invention relates to the use of cyclodextrin complexes containing lipoic acid, said complexes consisting of at least one representative of the series of unsubstituted α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, and at least one representative of the series of racemic α-lipoic acid, racemic dihydrolipoic acid and the derivatives thereof, for producing... Agent: Fulbright & Jaworski, LLP

20080020997 - Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods: Mutual prodrugs of glucosamine, and derivatives and analogs of glucosamine and an anti-inflammatory agent, compositions thereof, and methods for, e.g., treating disorders and conditions by administration of the compositions are provided. Topical compositions of glucosamine, and derivatives and analogs of glucosamine are also provided.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080020998 - Sustained release compositions for the therapeutic management of pain, inflammation and inflammation-associated disorders and prophylactic/ therapeutic methods thereof: Disclosed are sustained-release medicaments/drug compositions/formulations/therapeutics for the management of pain and inflammation associated disorders in general, more particularly arthritic inflammation. The sustained-release compositions comprise effective amounts of glucosamine, curcuminoids, boswellic acids and piperine.... Agent: Sabinsa Corporation

20080020999 - Fungicidal mixtures of amidinylphenyl compounds: Disclosed are fungicidal mixtures, compositions and methods for controlling plant diseases relating to combinations comprising (a) at least one compound selected from phenylamidines of Formula I, N-oxides, and agriculturally suitable salts thereof (I) wherein A is C3alkylene, optionally substituted with one or two methyl; W is CR5R6R7 or SiR8R9R10; and... Agent: E.i.du Pont De Nemours And Company Legal Patent Records Center

20080021001 - Methods for treating arthritic conditions in dogs: The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a hip or stifle of a canine which comprises administering to the canine a therapeutically effective amount of a bisphosphonate. The present invention also relates to method for eliciting a disease modifying... Agent: Merck And Co., Inc

20080021002 - Vitamin d compounds used to stabilize kidney transplants: A method of stabilizing kidney function in transplant patients is disclosed. In one embodiment, the method comprises the steps of kidney transplant patient, wherein the transplant patient is undergoing immunosuppressive therapy, with a sufficient amount of vitamin D compound whereby the kidney function stabilizes and wherein the development of interstitial... Agent: Quarles & Brady LLP

20080021003 - Extended step-down estrogen regimen: The present invention relates to methods for treating diseases, conditions or symptoms associated with deficient endogenous levels of estrogen comprising administration of a higher first dose of an estrogen followed by administration of a lower second dose of an estrogen once therapy has been effectively established. The invention further relates... Agent: Millen, White, Zelano & Branigan, P.C.

20080021004 - Sapogenin derivatives and their use in the treatment of cognitive dysfunction: The invention discloses the use of sapogenin derivatives in the treatment of cognitive dysfunction and similar conditions. Methods of treatment and pharmaceutical composition are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080021005 - Pegylated ion channel modulating compounds: This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds. Pharmaceutical compositions and methods of use of also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20080021006 - Pharmaceutical compositions: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080021007 - Substituted porphyrins: To improve bioavailability of the catalytic metalloporphyrin-based SOD mimics Mn(III) 5,10,15,20-tetrakis[N-ethylpyridinium-2-yl]porphyrin (MnTE-2-PyP5+) and Mn(III) 5,10,15,20-tetrakis[N,N′-diethylimidazolium-2-yl]porphyrin (MnTDE-2-ImP5+), three new Mn(III) porphyrins, bearing oxygen atoms within side chains, were synthesized and characterized: Mn(III) 5,10,15,20-tetrakis[N-(2-methoxyethyl)pyridinium-2-yl]porphyrin (MnTMOE-2-PyP5+), Mn(III) 5,10,15,20-tetrakis[N-methyl-N′-(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTM,MOE-2-ImP5+) and Mn(III) 5,10,15,20-tetrakis[N,N′-di(2-methoxyethyl)imidazolium-2-yl]porphyrin (MnTDMOE-2-ImP5+). The catalytic rate constants for O2 dismutation (and the related... Agent: Myers Bigel Sibley & Sajovec

20080021008 - Stent coatings comprising hydrophilic additives: A coating for implantable medical devices and a method for fabricating thereof are disclosed. The coating includes a mixture of a hydrophobic polymer and a polymeric hydrophilic additive, wherein the hydrophobic polymer and the hydrophilic additive form a physically entangled or interpenetrating system.... Agent: Squire, Sanders & Dempsey LLP

20080021012 - 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents: Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.... Agent: Astrazeneca R&d Boston

20080021009 - 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel 1,2,4-oxadiazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20080021010 - Azetidine glycine transporter inhibitors: The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.... Agent: Merck And Co., Inc

20080021011 - Therapeutic compounds: e

20080021013 - Jak inhibitors for treatment of myeloproliferative disorders: The invention provides a method for treating myeloproliferative disorders, myelodysplastic syndromes and other diseases, in which activation of JAK2 contributes to pathology, in a mammal comprising administering to the mammal an effective amount of a fused pyrrolocarbazole derivative wherein the fused pyrrolocarbazole derivative inhibits the activity of JAK2.... Agent: Cephalon, Inc.

20080021014 - Cyclic malonamides as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080021015 - Use as medicine of a compound restoring active principles in vivo: A method for delivering at least an active principal A to a human or animal, by administering, in vivo, an active compound of general formula A′V′C′, that is capable of restoring at least the entity A by cleavage, in vivo, of the corresponding attachments between A′ and V′, wherein V... Agent: Oliff & Berridge, PLC

20080021016 - Combined pharmaceutical composition for the inhibition of the decline of cognitive functions: The invention relates to a combined pharmaceutical composition for the inhibition of the decline of cognitive functions comprising as A) component (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7,7-trimethylbicyclo]-2-phenyl-1.7.-trimethylbicyclo[2.2.1]heptane of the formula (I) or a pharmaceutically acceptable acid addition salt thereof and as B) component a nootropic, an inhibitor of the acetylcholinesterase enzyme and/or a further pharmaceutical... Agent: K.f. Ross P.C.

20080021017 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents: which are useful in contraception and in treating melanoma, osteoporosis, acne, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, adenomyosis, infertility, endometriosis, endometrial cancer, polycystic ovary syndrome, cardiovascular disease, Alzheimer's disease, cognitive decline, central nervous system disorders, central nervous system cancers, leukemia, endometrial ablations, chronic renal disease, chronic hepatic disease,... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080021018 - (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate: The present invention is directed to (S)-(−)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate, to a method producing the dihydrate, and to a drug composition containing the dihydrate. The compound of the present invention has less hygroscopicity as compared with (S)-(−)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride anhydrous crystals and thus, exhibits excellent chemical stability.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080021019 - Kinase inhibitors: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080021020 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents: The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080021021 - Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist: An EP4 agonist is useful in ameliorating symptoms of lower urinary tract diseases such as (1) frequent urination, (2) urgency of urination, (3) pain in the reproductive organs and/or lower urinary tract (for example, bladder pain, urinary tract pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.)... Agent: Sughrue-265550

20080021022 - Substituted azole aromatic heterocycles as inhibitors of 11beta-hsd-1:

20080021023 - Morpholinyl and pyrrolidinyl analogs: The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080021024 - Metalloprotease inhibitors: The present invention relates to amide containing aromatic MMP inhibiting compounds with a mono-amide heteroaromatic group, of formulas I and II:... Agent: Amgen Inc.

20080021025 - Inhibitors of cathepsin s: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively... Agent: Genomics Institute Of The Novartis Research Foundation

20080021026 - Benzothiophene inhibitors of rho kinase: The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080021027 - Novel benzimidazole derivatives: e

20080021028 - N-hydroxyamide derivatives and use thereof: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080021029 - Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors: e

20080021032 - Pyrazole glucokinase activators:

20080021031 - Selenophene compounds: This invention relates to selenophene compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat cannabinoid-receptor mediated disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080021030 - Substituted pyrazoles as ppar agonists: i

20080021034 - Compositions and methods for modulating gated ion channels: The present invention relates to compositions and methods to modulate the activity of gated ion channels.... Agent: Lahive & Cockfield, LLP

20080021033 - Immuno inhibitory heterocyclic compounds: Compounds of formula (I) are CD80 inhibitors, and of value for immunomodulation, e.g. in rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis: wherein Y is —CH2—, —CH2CH2—, or CH2CH2CH2—; R1 represents H; F; methyl, trifuoromethyl, methoxy or triflioromethoxy; R3 represents H; F; CI; Br; NO2; CN;... Agent: Banner & Witcoff, Ltd.

20080021035 - Myosin light chain kinase inhibitor compounds, compostions and related methods of use: Pyridazinyl compounds, compositions and related methods of use.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20080021036 - Protein kinase c zeta inhibition to treat vascular permeability: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20080021037 - Isethionate salt of a selective cdk4 inhibitor: Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.... Agent: Pfizer Inc Steve T. Zelson

20080021038 - Novel piperidine/8-azabicyclo [3.2.1.] octan derivatives as modulators of chemokine receptor ccr5: Compounds of formula (I) wherein neither R4 nor R5 is hydrogen; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).... Agent: Morgan Lewis & Bockius LLP

20080021039 - Imidazopyridine-derivatives as inducible no-synthase inhibitors: m

20080021040 - Method and composition for treating periodontal disease: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably,... Agent: Law Offices Of Donald J. Pochopien

20080021041 - Chemical compounds: The present invention provides a method for the treatment of emesis in a mammal being treated with an opiod analgesic... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080021042 - Composition for controlling neuropathic pain: e

20080021043 - Piperidines and related compounds for treatment of alzheimer's disease:

20080021044 - N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2h)-pyrazineacetamide: The present invention is directed to N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-s-oxo-1(2H)-pyrazineacetamide, pharmaceutical compositions containing said compound and methods of treatment comprising inhibiting a serine protease using said compound. The present invention is further directed to a process for the preparation of the N-[2-[[(diaminomethylene)amino]oxy]ethyl]-3-[(2,2-difluoro-2-phenylethyl)amino]-6-methyl-2-oxo-1(2H)-pyrazineacetamide as a free base. The present invention is further directed to... Agent: Philip S. Johnson Johnson & Johnson

20080021045 - 7-amino-5-halopyrazolopyrimidines with a fungicidal action: e

20080021046 - Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by abnormal... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080021047 - C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase: The present invention provides C-purine nucleoside analogs and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV)... Agent: Merck And Co., Inc

20080021048 - Methods of treatment and prevention using haloaryl substituted aminopurines: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition,... Agent: Jones Day

20080021049 - Treatment of diet-related conditions using phospholipase-a2 inhibitors comprising indoles and related compounds: The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a phospholipase A2 inhibitor having comprising a substituted organic compound having... Agent: Michael B Harlin Mcandrews Held Malloy Ltd

20080021050 - Compounds, compositions, and methods: Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080021051 - Phycotoxins and uses thereof: Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission which are useful in treating anal fissure and other wounds and muscle disorders are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the... Agent: Knoble, Yoshida & Dunleavy

20080021052 - Novel glucokinase activators and methods of using same: a

20080021053 - Heterocyclic derivatives: The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.... Agent: Jeffrey M. Greenman

20080021054 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well... Agent: Wilson Sonsini Goodrich & Rosati

20080021055 - Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists: e

20080021056 - Fused, tricyclic sulfonamide inhibitors of gamma secretase: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080021057 - 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity: (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, Y and Z are defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including... Agent: Merck And Co., Inc

20080021059 - Antibacterial agents: The present invention is directed to a new class of triazolopyridine derivatives, to their use as antimicrobials, and to pharmaceuticals containing these compounds.... Agent: Pfizer Inc Steve T. Zelson

20080021058 - Pyrazolo '3,4-b! pyridine compounds and their use as phosphodiesterase type 4(pde4) inhibitors: e

20080021060 - Quinuclidine carbamate derivatives and their use as m3 antagonists: wherein R2 represents a benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl or thiophen-3-ylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbon atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p is 1 or 2 and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080021061 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity: (wherein n, R1, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis,... Agent: Merck And Co., Inc

20080021062 - Alkylsulphonamide quinolines: h

20080021063 - Compositions and methods for modulating sirtuin activity: The present invention is based, in part, on our discovery of compounds that inhibit an activity of a sirtuin (e.g., compounds that inhibit or preferentially inhibit an activity of SIRT2) and are therefore believed useful in the treatment or prevention of diseases associated with sirtuin activity. These diseases include, but... Agent: Fish & Richardson PC

20080021064 - Novel cyclic compound having quinolylalkylthio group: e

20080021065 - Novel benzamidine compound:

20080021066 - Iap inhibitors: Smac mimetics that inhibit IAPs.... Agent: Pepper Hamilton LLP

20080021067 - Methods for the treatment of substance abuse and addiction: The present invention relates to methods of treating and preventing substance addiction and substance abuse, including nicotine addiction and nicotine addiction-related disorders in a subject comprising administering a melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing substance addiction and substance... Agent: Merck And Co., Inc

20080021068 - Aqueous gel formulation and method for inducing topical anesthesia: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count.... Agent: Leydig Voit & Mayer, Ltd

20080021069 - Receptor function regulating agent: s

20080021070 - Pyridine derivatives, preparation and therapeutic application thereof: Wherein Z, R3 to R9 are as described herein. The invention also relates to methods of preparation of compounds of formula (I) and intermediates thereof. The compounds of this invention are active at CB1 cannabinoid receptor site, and are therefore, useful as pharmaceutical agents in treating a variety of diseases... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080021071 - 3-{4-(pyridin-3-yl) phenyl}-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents: Compounds of formula (I), as well as pharmaceutically-acceptable salts and pro-drugs thereof, are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.... Agent: Morgan Lewis & Bockius LLP

20080021072 - Porous plastic smoking cessation devices: A smoking cessation device is provided. The smoking cessation device includes a dispensing member comprising porous plastic defining a matrix of an internal network of passages in communication with pores on the exterior of the device. The device is preferably sized and structured like a cigarette or other combustible smoking... Agent: Krieg Devault LLP

20080021073 - Novel heterocyclic compounds: s

20080021074 - Pharmaceutical compositions and related methods of treatment: Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in... Agent: Wilson Sonsini Goodrich & Rosati

20080021075 - Treatment of pain: The invention relates to a new medicamentation for the treatment of pain, in particular fibromyalgia. The medicamentation comprises the administration of pramipexole in combination with an analgesic of the class of chemical compounds structurally related with gamma aminobutyric acid (GABA) selected from the group of pregabaline and gabapentine. The medicamentation... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080021076 - Treatment of pain: The invention relates to a new medicamentation for the treatment of pain, in particular fibromyalgia. The medicamentation comprises the administration of pramipexole and duloxetine. The medicamentation is a combination of pramipexole an duloxetine which may be used in a fixed dose combination as well as in a free dose combination.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080021077 - Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where... Agent: Foley And Lardner LLP Suite 500

20080021078 - Methods and medicaments for administration of ibuprofen: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in separate compartments, is administered three times per day.... Agent: Townsend And Townsend And Crew, LLP

20080021079 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080021080 - 5-lipoxygenase inhibitors: The present invention relates to 5-lipoxygenase inhibitors. Compounds disclosed herein can be useful in the treatment of bronchial asthma, chronic obstructive pulmonary disorder, arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, urticaria, atopic dermatitis, allergic rhinitis, other inflammatory and autoimmune... Agent: Ranbaxy Inc.

20080021081 - Cyclopropyl amine derivatives: e

20080021082 - Small molecule inhibition of a pdz-domain interaction:

20080021083 - 4-methylpyrazole formulations for inhibiting ethanol intolerance: Methods, articles of manufacture and compositions are provided useful for the prevention or amelioration of a symptom of acetaldehyde accumulation or ethanol intolerance in a subject with reduced or absent reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity wherein about 1 mg/kg to about 4 mg/kg 4-methylpyrazole, or an... Agent: Jones Day

20080021084 - Derivatives of pyrazoline, procedure for obtaining them and use thereof as therapeutic agents: t

20080021085 - Method of reducing abeta42 and treating diseases: The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and... Agent: Myriad Genetics Inc. Intellecutal Property Department

20080021087 - Cannabinoid receptor modulator: e

20080021086 - Pharmaceutical composition for prevention or treatment of lipid metabolism disorder: The present invention provides pharmaceutical compositions for the prevention or treatment of lipid metabolism disorders. The pharmaceutical compositions comprising, as an active ingredient, (2S)-2-benzl-3-(cis-hexa hydro-2-isoindolinylcarbonyl)propionic aid (generic name: mitiglinide) or a pharmaceutically acceptable salt thereof, or a hydrate thereof exert remarkable lipid metabolism improving effect, and are useful for, for... Agent: Frenkel & Associates

20080021088 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities: Described and claimed are compounds of Formula (I) in which R, R′, R″, A, and D have the meanings described in the text, as useful agents in the cure of pathologies characterized by altered angiogenesis and as antitumorals.... Agent: Frommer Lawrence & Haug

20080021090 - Chrystalline duloxetine hydrochloride: Crystalline duloxetine hydrochloride, compositions containing the same and methods for the production thereof.... Agent: Leslie Meyer-leon, Esq.IPLegal Strategies Group P.C.

20080021089 - Crystalline duloxetine hydrochloride: Crystalline duloxetine hydrochloride, compositions containing the same and methods for the production thereof.... Agent: Leslie Meyer-leon, Esq.IPLegal Strategies Group P.C.

20080021091 - Crystalline duloxetine hydrochloride: Crystalline duloxetine hydrochloride, compositions containing the same and methods for the production thereof.... Agent: Leslie Meyer-leon, Esq.IPLegal Strategies Group P.C.

20080021092 - Stable pharmaceutical compositions of orlistat: The present invention relates to stable pharmaceutical compositions of orlistat for treatment or prevention of obesity and hyperlipidemia. The pharmaceutical compositions contain Orlistat form I, which does not convert to form II at the temperatures encountered during manufacturing of an orlistat dosage form.... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080021093 - Oxidation process with enhanced safety useful in the manufacture of moxidectin: e

20080021094 - Treatments for neurogenetic disorders, impulse control disorders, and wound healing: The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080021096 - Methods of using flavonoids to enhance memory: Described herein are flavonoids (e.g., 5-desoxy flavones and/or 5-desoxy flavonols, including without limitation fisetin and its derivatives) that activate ERK and induce CREB phosphorylation in neuronal cultures, facilitate long-term potentiation in hippocampal slices and enhance object recognition in vivo. Methods of using these flavonoids, for instance, for enhancing memory are... Agent: Klarquist Sparkman, LLP

20080021095 - Small molecule antagonists of xiap family proteins: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of XIAP family proteins. In particular, the present invention provides embelin and other XIAP inhibitors and methods of using these compounds as antagonists of the anti-apoptotic effects of XIAP family member proteins. The present invention also provides... Agent: Casimir Jones, S.c.

20080021097 - Arginase levels/activity: This invention relates to compositions, and methods of use thereof, for treating conditions associated with elevated arginase levels and/or activity comprising administering to a subject in need thereof, certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof.... Agent: Nada Jain, P.C.

20080021098 - Antifungal compositions: A method of simultaneously preventing the growth of fungi on substrates, particularly those exposed to an atmosphere, and imparting thereto a desired odour, by applying thereto a fragrance whose fragrant properties are derived mainly from the presence in the fragrance of at least two fragrance components selected from the group... Agent: Norris, Mclaughlin & Marcus

20080021099 - 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune disease: The present invention is directed to the use of 5-cyano-prostacyclin derivatives as therapeutics for the treatment of autoimmune diseases.... Agent: Jacqueline S Larson

20080021100 - Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders: The present invention provides compositions as well as kits and methods based on a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 that are useful for treating inflammatory disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080021101 - Method of preparing a latanoprost opthalmic solution and the resulting solution: A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method,... Agent: Knobbe Martens Olson & Bear LLP

20080021102 - Method for the management of incontinence: A composition and a dosage form are disclosed comprising oxybutynin alone/or accompanied by another drug indicated for therapy. A method is disclosed for administering oxybutynin alone/or accompanied by a different drug or for administering oxybutynin and a different drug according to a therapeutic program for the management of incontinence alone,... Agent: Woodcock Washburn LLP

20080021103 - Mucoadhesive composition: The invention is directed to a topical medicament-containing composition which exhibits excellent bioadhesive properties suitable for application to the human body, including to mucous membranes.... Agent: Wyeth Patent Law Group

20080021104 - Liquid compositions of calcium acetate: The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.... Agent: Foley And Lardner LLP Suite 500

20080021105 - Medicine capable of inhibiting activation of transcription factor klf5: A medicament having an action of inhibiting activation of transcription factor KLF5 and thus inhibiting vascular remodeling and arteriosclerosis, which comprises an acyclic polyprenyl compound (e.g., polyprenylcarboxylic acid such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid and the like) as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20080021106 - Cellular uptake of bioactive agents: Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20080021107 - Use of amino acids for treatment of various conditions: A method of treating a patient for a condition characterized by symptoms that can be alleviated by interfering with or supplementing the activity of endogenous ligands on the α2δ subunit of a voltage gated calcium channel, said method comprising: administering to a patient experiencing the condition an amount of one... Agent: Nixon Peabody LLP - Patent Group

20080021109 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20080021108 - Memory fixation accelerator: A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthaleny)carbamoyl]benzoic acid or 4- [(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.... Agent: Greenblum & Bernstein, P.L.C

20080021110 - Production of gossypol co-crystals: This invention relates to relates to methods for producing gossypol acetic acid co-crystals and (−)-gossypol acetic acid co-crystals. The invention also relates to pharmaceutical compositions comprising gossypol acetic acid co-crystals and (−)-gossypol acetic acid co-crystals and the use of gossypol acetic acid co-crystals and (−)-gossypol acetic acid co-crystals for inducing... Agent: Medlen & Carroll, LLP

20080021111 - Method of treating men suffering from chronic nonbacterial prostatitis with serm compounds or aromatase inhibitors: A method for treatment or prevention of chronic nonbacterial prostatitis in individuals without urethral sphincter dysfunction, comprises administering an effective amount of (i) a selective estrogen receptor modulator (SERM) having estrogen antagonist effect in the prostate, (ii) an aromatase inhibitor, and/or (iii) an antiestrogen.... Agent: Fitzpatrick Cella Harper & Scinto

20080021112 - Long chain alcohols provided in edible oils: The present invention provides a method for incorporating long chain alcohols into edible oils. The long chain alcohol/edible oil admixture is then suitable for use in preparation of various foods. The long chain alcohol is added by the introduction of energy and in a preferred embodiment in the absence of... Agent: Philip S. Johnson Johnson & Johnson

20080021113 - Organic compositions: The present compositions related to cleaning and disinfecting compositions particularly useful in the treatment of hard surfaces. The compositions are hard surface cleaning and disinfecting compositions which comprise a combination of a quaternary ammonium compound and an acetylenic diol surfactant compound.... Agent: Norris, Mclaughlin & Marcus

20080021114 - Compositions and methods for the prevention and treatment of diseases in plants: Non-toxic, environmentally friendly, naturally-derived and economical compositions and methods for treating and preventing bacterial or fungal disease in plants, especially disease caused by Xanthomonas species, such as citrus canker, wherein such compositions include d-limonene alone or in combination with wax and/or wax extract, monohydric alcohol, an emulsifier and/or other ingredients... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20080021115 - Layered double hydroxides that delaminate in water, their manufacturing process and use: wherein M(II) is Mg, Zn or a combination thereof, M(III) is Al, and x is 0.2 to 0.33 and a plurality of intercalated layers between each adjacent basal layers of Mg acetate, Zn acetate or Ce acetate and water of intercalation. A process for producing the layered double hydroxide is... Agent: Millen, White, Zelano & Branigan, P.C.

20080021116 - Pyruvate-kinase as a novel target molecule: This invention relates to the use a pyruvate-kinase or a nucleic acid coding therefor as a target for the modulation of apoptotic processes, particularly as a target molecule for the diagnosis, prevention or treatment of apoptosis-associated disorders, such as tumours.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

  
01/17/2008 > patent applications in patent subcategories. USPTO class listing

20080015138 - Metal binding compounds, metal binding compositions, and their uses: Compositions are provided comprising a family of peptides having binding specificity for metal, and their use to produce coating compositions. The coating compositions are used to deliver a pharmaceutically active agent to metal, and are used in methods related to metal implants, metal repair, and metal-related diseases.... Agent: Affinergy, Inc.

20080015142 - Glycopegylated follicle stimulating hormone: The present invention provides conjugates between follicle stimulating hormone and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of... Agent: Morgan, Lewis & Bockius LLP (sf)

20080015141 - Use of a novel polymorphism in the hsgk1 gene in the diagnosis of hypertonia an use of the sgk gene family in the diagnosis and therapy of the long qt syndrome: e

20080015144 - Glp- (9-36) methods and compositions: Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) compositions are also provided.... Agent: Amster, Rothstein & Ebenstein LLP

20080015143 - In vitro methods for detecting renal cancer: The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search,... Agent: Intellectual Property / Technology Law

20080015145 - Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions: Mimotope receptors and inhibitors employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, such as liposomes, to act as synthetic platelets, for example, by providing binding sites for binding... Agent: David S. Resnick

20080015159 - Small synthetic rna, a method of preparing the same and uses thereof: Translation of the hepatitis C virus (HCV) RNA is mediated by the interaction of ribosomes and cellular proteins with an internal ribosome entry site (IRES) located within the 5′untranslated region (5′UTR). We have investigated whether small RNA molecules corresponding to the different stem-loop (SL) domains of the HCV IRES, when... Agent: Dewitt Ross & Stevens S.c.

20080015168 - Termite-proofing agent and its application method: The present invention is a composition comprising a neonicotinoid-based compound having a high degree of insecticide activity, an organic solvent and a surfactant. The present invention is also a method that allows the obtaining of lumber that does not require termite-proofing treatment following production of lumber by injecting this composition... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080015137 - Methods and compositions for targeting macromolecules into the nucleus: The present invention includes compositions, methods and kits for directing an agent across the nuclear membrane of a cell. The present invention includes a Karyopherin beta2 translocation motif in a polypeptide having a slightly positively charged region or a slightly hydrophobic region and one or more R/K/H-X(2-5)-P-Y motifs. The polypeptide... Agent: Chalker Flores, LLP

20080015139 - Soluble virus-specific t-cell receptor compositions: Compositions and methods for diagnosing a viral infection and methods of inhibiting such an infection are described. The methods are based on the identification of T-cell receptor gene sequences from cytotoxic T cell clones that are specific for HIV-1 or HCV. Soluble T-cell receptor compositions that bind to HLA class... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080015140 - Disinfecting composition: The invention relates to preparations that can be used for disinfecting and that can be applied in the national economy, medicine, and laboratories of all types. The preparation contains a chelating metal complex compound with a monodentate, bidentate, or polydentate ligand that exhibits affinity to hydrogen ion, an ionogenic surfactant,... Agent: Alston & Bird LLP

20080015151 - Cyanovirin variant-polymer conjugates: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof, and methods of preparing such conjugates. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.... Agent: Perkins Coie LLP

20080015146 - Dpp-iv inhibitors: e

20080015149 - Galectin 11: The present invention relates to novel galectin 11 proteins which are members of the galectin superfamily. In particular, isolated nucleic acid molecules are provided encoding the human galectin 11 proteins. Galectin 11 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080015148 - Il-1 antagonist formulations: Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID... Agent: Regeneron Pharmaceuticals, Inc

20080015147 - Method for inhibiting neuronal cell death: This invention relates to a method of inhibiting neuronal cell death, including protecting neronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C Associate Peptide (TCAP). The invention provides the use of TCAP... Agent: Mccarthy Tetrault LLP

20080015154 - Methods and systems for neural maintenance and regeneration: Methods and systems are described that release one or both of a neurotrophin and an inhibitor of the degradation of the neurotrophin within or in the vicinity of a highly innervated tissue. In some embodiments, the method includes regulating the release of the neurotrophin and the inhibitor of degradation over... Agent: Searete LLC Clarence T. Tegreene

20080015150 - Peptides and derivatives thereof showing cell attachment, spreading and detachment activity: The present invention relates to peptides and derivatives thereof showing cell attachment, spreading and detachment activity. Particularly, the present invention relates to the peptide NKDIL and EPDIM and derivatives thereof which promote the cell attachment activity through interaction with α 3β 1 integrin as a functional cell receptor and include... Agent: Jhk Law

20080015153 - Pharmaceutical compositions containing the long pentraxin ptx3: Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumour diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells,... Agent: Nixon & Vanderhye, PC

20080015152 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising petide sequence (Z) covalently bound to X.... Agent: Clark & Elbing LLP

20080015155 - Compositions and methods for the treatment of inflammatory conditions of the mucosae, skin and the eye: The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis(eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an inflammatory... Agent: Marshall, Gerstein & Borun LLP

20080015156 - Novel 2-substituted methyl penam derivatives: wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or —COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted... Agent: Oliff & Berridge, PLC

20080015157 - Novel water-soluble prodrugs: e

20080015162 - Compounds and methods for modulating gene expression: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Schwegman Lundberg Woessner & Kluth P.A.

20080015158 - Inhibition of the expression of huntingtin gene: It is intended to provide methods for suppressing the huntingtin gene expression by using a double-stranded RNA (dsRNA), huntingtin gene expression inhibitors to suppress the huntingtin gene expression, and preventives and/or remedies of Huntington's disease. Targeting against a specific sequence of mRNA at immediately upstream of CAG repeats in HD... Agent: Alston & Bird LLP

20080015160 - Method for detecting cancer and a method for suppressing cancer: An object of the invention is to find a cancer-associated gene to be used as an index for detecting canceration of cells and degree of malignancy of cancer, so as to to provide a method for detecting cancer using the cancer-associated gene as an index and provide a method of... Agent: Birch Stewart Kolasch & Birch

20080015164 - Methods and compositions for inactivation of dihydrofolate reductase: Disclosed herein are methods and compositions for inactivating dihydrofolate reductase genes, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.... Agent: Robins & Pasternak

20080015163 - Mice lacking alpha 1g showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1g t-type calcium channels: The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases... Agent: Klarquist Sparkman, LLP

20080015165 - Novel polypeptide: This invention relates to a novel polypeptide having an α1,3-fucosyltransferase activity, a method for producing the polypeptide, a DNA encoding the polypeptide, a method for producing the DNA, a recombinant vector obtained by inserting the DNA thereinto, a transformant having the recombinant vector, an antibody recognizing the polypeptide, a method... Agent: Fitzpatrick Cella Harper & Scinto

20080015161 - Rnai modulation of tgf-beta and therapeutic uses thereof: The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.... Agent: Fish & Richardson PC

20080015166 - Barrier integrity in hiv patients: The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.... Agent: Foley And Lardner LLP Suite 500

20080015167 - Synergistic and residual pesticidal compositions containing plant essential oils: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils and/or their constituents, plant essential oils and/or their constituents in admixture with known active pesticidal compounds or plant essential oils and/or their constituents in admixture with other compounds not previously used as active ingredients in pesticidal... Agent: Nixon & Vanderhye, PC

20080015169 - Amino-methyl substituted tetracycline compounds: Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.... Agent: Lahive & Cockfield, LLP

20080015170 - Method of treating menopausal women transdermally with testosterone: A method for administering testosterone to a menopausal woman in need of receiving transdermal testosterone therapy wherein the woman is being coadministered estrogen. The type and route of administration of the estrogen are determined and then changed according to the invention. Testosterone is transdermally administered to the woman. Also, a... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080015171 - Method for increasing absorption of steroid hormones: Compositions and methods are disclosed wherein one or more steroid hormones are combined in a mixture with a sulfur-containing compound. The sulfur-containing compound increases the absorption of the steroid hormone through a mucosal surface, such as skin, oral mucosa, and mucosa of the gastrointestinal tract.... Agent: Edward E. Roberts

20080015172 - Caspase inhibitors and uses thereof: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3is a group capable of fitting into the... Agent: Vertex Pharmaceuticals Inc.

20080015173 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20080015174 - Metabolic disease treatments: The invention relates to the use of compounds to treat a number of conditions, such as a pre-diabetes condition, type 1 diabetes, type 2 diabetes, hyperglycemia, insulin resistance and glucose intolerance. Compounds that can be used in one or more of the treatment methods include 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3α,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,7β,16α,17β-tetrahydroxyandrost-5-ene, 3β,16α,17β-trihydroxyandrost-5-ene-7-one, 3β,7β,17β-trihydroxy-17α-ethynylandrost-5-ene,... Agent: Hollis-eden Pharmaceuticals, Inc.

20080015175 - Novel tellurium compounds and their use as immunomodulators: Novel tellurium-containing compounds and uses thereof as immunomodulators are disclosed.... Agent: Martin D Moynihan Prtsi Inc

20080015176 - New paediatric indications for direct thrombin inhibitors: The invention relates to new paediatric indications for direct thrombin inhibitors such as dabigatran etexilate.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080015177 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.... Agent: Goodwin Procter LLP Patent Administrator

20080015178 - Benzimidazoles, process for their preparation and use thereof as medicament: e

20080015179 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien

20080015180 - Methods and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+related disease.... Agent: Lahive & Cockfield, LLP

20080015181 - Pharmaceutical compositions comprising droxidopa: The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering... Agent: Alston & Bird LLP

20080015182 - Potent parp inhibitors: e

20080015183 - Substituted quinazolin-4-ylamine analogues: Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for... Agent: Edward Angell Palmer & Dodge, LLP Client: Neurogen Corporation

20080015185 - N-heterocyclic inhibitors of tnf-alpha expression: b

20080015184 - Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines: Imidazopyridine, imidazoquinoline, and imidazonaphthyridine compounds having a urea substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20080015186 - Pharmaceutical compositions containing in combination a cannabinoid receptor antagonist and an antipsychotic: This invention discloses and claims various pharmaceutical compositions containing in combination a pyrazole-based cannabinoid receptor antagonist and an antipsychotic.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080015187 - Hiv integrase inhibitors: wherein Z is O or N(R8); n is an integer equal to zero or 1; and R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and... Agent: Merck And Co., Inc

20080015188 - Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives: Provided are stable pharmaceutical compositions comprising from about 2.5% to about 20% of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative by weight of the composition and at least one pharmaceutically acceptable excipient, wherein the composition preferably has a total weight of less than 100 mg. Also provided are stable pharmaceutical compositions comprising a... Agent: Kenyon & Kenyon LLP

20080015189 - Antimicrobial photoinactivation using chalcogen analogs of benzo(a)phenoxazinium dyes: Compositions and methods for the use of photoactivatable antimicrobial chalcogen analogs of benzophenoxazinium dyes in the treatment of infections are provided.... Agent: Edwards Angell Palmer & Dodge LLP

20080015190 - Inhibitors of histone deacetylase: The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases. Further,... Agent: Merck And Co., Inc

20080015192 - Inhibitors of polo-like kinases: Compounds that inhibit Plk1, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20080015191 - Pyrazines and pyridines and derivatives thereof as therapeutic compounds: The present invention pertains to certain pyrazines and pyridines, and derivatives thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: (I) wherein: Q is independently —N═ or —CH═; one of RP2 and RP3 is independently... Agent: Michael Best & Friedrich LLP

20080015193 - Certain azoles exhibiting atp-utilizing enzyme inhibitory activity, compositions, and uses thereof: Certain oxazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080015194 - Methods and compositions of targeted drug development: The present invention is directed to methods for developing one or more drugs for one or more targeted therapies and compositions derived therefrom. In accordance with one aspect of the present invention, combinatorial chemistry techniques for use with high throughput screening techniques for identifying small molecule affinity and/or activity interactions... Agent: Sonnenschein Nath & Rosenthal LLP

20080015195 - Novel heteroaromatic inhibitors of fructose-1,6-bisphosphatase: e

20080015196 - Imidazopyrazines, imidazopyridines, and imidazopyrimidines as crf1 receptor ligands: Novel aryl substituted imidazopyrazines, imidazopyrimidines, and imidazopyridines are provided. Such compounds can act as selective modulators of CRF receptors. The imidazopyrazines, imidazopyrimidines, and imidazopyridines compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods... Agent: Edwards Angell Palmer & Dodge LLP

20080015197 - Process for the preparatrion of zopiclone: Provided is a process for the preparation of zopiclone, an intermediate in the synthesis of eszopiclone.... Agent: Kenyon & Kenyon LLP

20080015198 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substitute pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Banner & Witcoff, Ltd.

20080015199 - Triazolone derivatives: e

20080015200 - Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor: Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20080015201 - Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080015202 - Thiazole derivatives having vap-1 inhibitory activity: and G is optionally protected amino, then D should be —CS—, or then A should be lower alkylene, B or E should be —NH— and F should be —CO—; or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor as well as a pharmaceutical composition and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080015203 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl,... Agent: Morgan Lewis & Bockius LLP

20080015204 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: m

20080015205 - Cancer combination therapy comprising azd2171 and imatinib: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor... Agent: Morgan Lewis & Bockius LLP

20080015206 - Anti-cancer cyclopenta[g]quinazoline compounds: e

20080015207 - Methods for treating androgen receptor related disorders: One embodiment is directed toward a method for treating an individual with a disorder affected by androgen receptor activity. This method includes administering a therapeutic amount of DL3 (6-amino-2-(2-4-tert-butyl-phenoxy)-ethylsulfanyl)-1H-pyrimidin-4-one) to the individual. In an additional embodiment, the disorder affected by androgen receptor activity includes cancer. Another embodiment is directed toward... Agent: Dinsmore & Shohl, LLP

20080015208 - Arylsulfonamidyl tetralin derivatives and uses thereof: e

20080015209 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.... Agent: Lewis J. Kreisler

20080015210 - Base-stabilized polyorthoester formulations: A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of... Agent: Heller Ehrman LLP

20080015211 - Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists: Methods for the treatment of inflammatory and ulcerative diseases of the bowel (e.g., Crohn's disease and ulcerative colitis) with low dose opioid antagonists (e.g., naltrexone, nalmefene or naloxone), pharmaceutical compositions for use in such methods, and methods for the manufacture of such pharmaceutical compositions. An embodiment of the invention includes... Agent: Mcnees Wallace & Nurick LLC

20080015212 - Inhibitors of akt activity: The instant invention provides for canthine analogs that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need... Agent: Merck And Co., Inc

20080015213 - Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to macrocyclic aminopyridyl compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising... Agent: Merck And Co., Inc

20080015214 - 3-piperidin-4-yl-indole orl-1 receptor modulators: e

20080015215 - Diamine derivatives: The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS),... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080015217 - Antioxidant combinations for use in ruminant feed rations: The present invention provides a combination of antioxidants that effectively stabilize different types of fats utilized in a ruminant diet. When included in a ruminant feed ration or water source, the antioxidant combination typically increases nutrient digestion, such as fiber and protein, improves rumen fermentation, improves microbial growth, improves microbial... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080015218 - Antioxidant combinations for use in ruminant feed rations having a fat source: The present invention provides a combination of antioxidants that effectively stabilize different types of fats utilized in a ruminant diet. When included in a ruminant feed ration or water source, the antioxidant combination typically increases nutrient digestion, such as fiber and protein, improves rumen fermentation, improves microbial growth, improves microbial... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20080015219 - Therapeutic compounds: e

20080015216 - Histone deacetylase inhibitors: This invention relates to hydroxamic acid derivatives having a sulfonamide linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and... Agent: Merck And Co., Inc

20080015220 - Biphenyl derivatives: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl... Agent: Theravance, Inc.

20080015221 - Compound capable of cytoskeleton and induction of cell elongation and process for synthesizing the same: A compound capable of cytoskeleton and induction of cell elongation, 7-chloro-6-piperidin-1-yl-quinoline-5,8-dione with a chemical formula of C14H13CIN2O2, is designated as PT-262. The PT-262 can induce cell elongation by stabilization of the F-actin and induction of the abnormal actin polymerization in cancer cells, further, the PT-262 possesses antitumor activity and can... Agent: Dr. Banger Shia

20080015222 - New heterocyclic amides: c

20080015223 - Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention relates to certain pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke,... Agent: Fish & Richardson P.C.

20080015224 - Nitroxide superoxide dismutase mimetics to treat extracellular superoxide dismutase deficiencies: The invention relates to methods and uses of tempol or other nitroxide superoxide dismutase (SOD) mimetics for the treatment of extracellular-superoxide dismutase (EC-SOD) deficiencies.... Agent: Knobbe Martens Olson & Bear LLP

20080015225 - Dimeric piperidine derivatives: e

20080015226 - Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors: The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridynyl alkylene alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.... Agent: Ladas & Parry

20080015227 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: e

20080015228 - Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases: This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CB1 receptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080015229 - Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes: The invention relates to the use of rimonabant, either alone or combined with another active ingredient, for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes or non-insulin-dependent diabetes and/or its complications.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080015230 - Heterocyclic derivatives and their use as therapeutic agents: e

20080015231 - Therapeutic compounds:

20080015232 - Schweinfurthin analogues: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.... Agent: Viksnins Harris & Padys Pllp

20080015233 - 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to 2,4,6-substituted pyridyl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20080015234 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: e

20080015236 - Method for promoting myocardial regeneration and uses thereof: The present invention provides a method for promoting myocardial regeneration in a subject. Additionally, the present invention provides a method for promoting myocardial cell and tissue regeneration in a subject. The present invention is further directed to the use of GM-284 in promoting myocardial tissue regeneration in a subject. Finally,... Agent: Sander Rabin Md Jd Convergent Technology Patent Law Group

20080015235 - Histamine h3 receptor inhibitors, preparation and therapeutic uses: e

20080015238 - Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals:

20080015237 - New compounds i/418:

20080015239 - Therapeutic substituted pyrrolidone compounds:

20080015240 - Acid salt of benzimidazole derivative and crystal thereof: The present invention provides acid salts, such as sulfate, hydrochloride, and methanesulfonate, of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid and the crystals thereof. These benzimidazole derivatives and the crystals thereof have an in vivo chymase inhibitory activity and can be used as a preventive or therapeutic agent for inflammatory diseases, allergic diseases, respiratory diseases,... Agent: Sughrue Mion, PLLC

20080015241 - All day rhinitic condition treatment regimen: A therapeutic regimen and method of treating a rhinitic condition is provided comprising a first pharmaceutical dosage form comprising a first therapeutically effective amount of an antihistamine and a therapeutically effective amount of an anticholinergic; a second pharmaceutical dosage form comprising a second therapeutically effective amount of an antihistamine and... Agent: Intellectual Property / Technology Law

20080015242 - Indole compounds as beta3 androceptor agonist: or a salt thereof, wherein R1 is a hydrogen atom or the like; R2 is NHSO2R3 or the like; R3 is a (C1-C6)alkyl group or the like; R5 is a hydrogen atom or the like; R6 and R7 may be the same or different and are each independently a hydrogen... Agent: Young & Thompson

20080015244 - Disubstituted pyrazolyl carboxanilides:

20080015243 - Small molecule modulators of hepatocyte growth factor (scatter factor) activity: and pharmaceutically acceptable derivatives thereof, wherein R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities... Agent: Choate, Hall & Stewart LLP

20080015245 - 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics: d

20080015246 - Novel ligands that modulate rar receptors and pharmaceutical/cosmetic compositions comprised thereof:

20080015249 - Cancer treatment compositions and method using natural plant essential oils: Pharmaceutical compositions containing plant essential oils, natural or synthetic, or mixtures or derivatives thereof, for the prevention and treatment of soft tissue cancer in mammals.... Agent: Nixon & Vanderhye, PC

20080015248 - Polyphenol proteasome inhibitors, synthesis, and methods of use: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080015247 - Quercetin-containing compositions: This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080015250 - Ultraviolet absorbing ophthalmic compositions: The present invention is directed to a composition comprising: (a) one or more UV-absorbing agents, wherein all the UV-absorbing agents are in solution; and (b) an excipient; wherein the composition is ophthalmically acceptable, and wherein the composition does not contain an active agent. In some embodiments, the UV-absorbing agent is... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080015251 - Means and method for treating lipotoxicity and other metabolically related phenomena: A method for treating symptoms of a lipotoxicity-related phenomenon includes introducing into a patient a therapeutically effective synergistic amount of a phenomenon-inhibiting cocktail of a polyphenol (P), thiol antioxidant (To) and ascorbic acid (A) to reduce intracellular reactive oxygen species (ROS) and/or increase intracellular nitrite (NO), so that reduction of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080015252 - Therapeutic agent for virus-associated malignancy: A therapeutic agent comprising fucoxanthin or fucoxanthinol as an active component is disclosed. The therapeutic agent is effective and high clinical utility for medical treatment and prevention of virus-associated malignancy such as adult T-cell leukemia and Burkitt lymphoma.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080015253 - Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof: t

20080015254 - Compounds for the treatment of metabolic disorders:

20080015255 - Pharmaceutical compositions based on fluorinated sulphamides and sulphinimides:

20080015256 - Tetralin and indane derivatives and uses thereof:

20080015257 - Compositions and methods for reducing body fat: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.... Agent: Goodwin Procter LLP Patent Administrator

20080015258 - L-(-)-moprolol l-(+)-tartrate: L-(−)-moprolol L-(+)-tartrate salt (2:1), method for preparing it and pharmaceutical composition comprising it.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080015259 - Substantially pure o-desmethylvenlafaxine and processes for preparing it: Methods for preparing substantially pure O-desmethylvenlafaxine are described.... Agent: Kenyon & Kenyon LLP

20080015260 - Pharmaceutical compositions having improved stability and methods for preparation and use: The present invention relates to novel compositions having improved stability during storage over extended periods of time. The compositions of the present invention comprise an active pharmaceutical ingredient combined with a synthetic form of magnesium aluminum silicate. The present invention also relates to novel compositions that comprise active pharmaceutical ingredients... Agent: Marla J. Church, Esq. Kiel Laboratories, Inc.

20080015261 - Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function: The invention relates to the use of an accelerated lymphocyte homing agent, e.g. a 2-amino-1,3-propanediol derivative, in reducing delayed graft function in a recipient of organ or tissue transplant.... Agent: Novartis Corporate Intellectual Property

20080015262 - Pest treatment composition: The present invention provides a pediculicidal and ovicidal composition with an extraordinarily lethal effectiveness that can also be used to remove parasites, such as lice. The pediculicidal and ovicidal composition contains a purified terpene agent such as citronellal, citronellol, citronellyl or a mixture thereof, a short chain alcohol, and a... Agent: Sutherland Asbill & Brennan LLP

20080015263 - Compositions for delivery of therapeutics and other materials: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20080015264 - Encapsulated flavor and/or fragrance preparations: This invention relates to encapsulated flavor and/or fragrance preparations and a method for producing same from a spray solution consisting of an aqueous solution of polymeric carriers and emulsified flavors and/or fragrances. The granules have an adjustable particle size of between 0.2 and 2 mm, present even size distribution and... Agent: Akerman Senterfitt

20080015265 - Methods of treating obesity using satiety factors: The present invention provides methods of treating or preventing disorders or conditions associated with an undesirable level of a satiety factor by administering to a subject in need thereof an effective amount of an agonist or antagonist of a satiety factor. The present invention also provides methods of selecting a... Agent: Jones Day

  
01/10/2008 > patent applications in patent subcategories. USPTO class listing

20080009437 - Pharmaceutical compositions and method for treating dry eye: A composition for treating or reducing a dry eye condition or an ophthalmological disorder that has an etiology in inflammation comprises a dissociated glucocorticoid receptor agonist (“DIGRA”). The composition can be formulated for topical application, injection, or implantation.... Agent: Bausch & Lomb Incorporated

20080009439 - Compositions and methods of use for a fibroblast growth factor: The present invention generally relates to compositions and methods of use for a fibroblast growth factor (“FGF”). More particularly, the present invention relates to a nucleotide polymorphism (SNP) of FGF-20, and its fragments, derivatives, variants, homologs, and analogs, as well as their uses in wound healing, and prevention and/or treatment... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo

20080009440 - Soothing agent and food for treating fatigue: e

20080009449 - Lignan complex derived from flax seed used for treatment of hypercholesterolemic atherosclerosis: A method of treating hypercholesterolemic atherosclerosis in a mammal exhibiting symptoms of the disease. The method comprises administering to the mammal an effective amount of a lignan complex derived from flax and containing about 34 to 38% by weight of secoisolariciresinol diglucoside. The invention also relates to compositions and uses... Agent: Kirby Eades Gale Baker

20080009453 - Pharmceutical compositions containing polydatin or its salts and their application: The invention discloses pharmaceutical compositions containing polydatin or its pharmaceutically acceptable salts with the effect of improving microcirculation, and their application in preparing drugs which can improve microcirculation. The compositions are an non-gastrointestinal injection preparation, the preparation can be an aqueous solution which have pH 7.0-10.0 comprising 5-50% propandiol. The... Agent: Raymond Y. Chan

20080009454 - Polynucleotide: A polynucleotide consisting of the base sequence of SEQ ID NO: 2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at... Agent: Fish & Richardson P.C.

20080009465 - Novel glucokinase activators and methods of using same: p

20080009434 - Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same: A nanostructure composed of a plurality of peptides, each peptide containing at least one aromatic amino acid, whereby one or more of these peptides is end-capping modified, is disclosed. The nanostructure can take a tubular, fibrillar, planar or spherical shape, and can encapsulate, entrap or be coated by other materials.... Agent: Martin D Moynihan Prtsi, Inc.

20080009433 - Use of glp-1 or analogs in treatment of myocardial infarction: This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.... Agent: Eli Lilly & Company

20080009436 - Cyclosporin compositions: A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols,... Agent: Allergan, Inc.

20080009435 - Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them: c

20080009445 - Anti-endotoxic, antimicrobial cationic peptides, the encoding dna and methods of use thereof: A novel class of cationic peptides having antimicrobial activity is provided. Exemplary peptides of the invention include KWKSFIKKLTSAAKKVVTTAKPLALIS (SEQ ID NO:3) and KGWGSFFKKAAHVGKHVGKAALTHYL (SEQ ID NO:15). Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Such methods are useful for the treatment of... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20080009444 - Biologically active complex of nr6 and cardiotrophin-like-cytokine: The present invention relates generally to a biologically active complex comprising at least two heterologous molecules. More particularly, the biologically active complex of the present invention comprises at least two polypeptides or parts, fragments, truncates or protease-activated forms of one or more of the polypeptides wherein the complex alone or... Agent: Leopold Presser, Scully, Scott, Murphy & Presser

20080009443 - Diafiltration system to fractionate protein mixtures: The present invention provides a method for the separation of proteins on the basis of molecular weight by use of a multi-segment fractionation chamber based on the principles of diafiltration. In addition, the present invention provides an effective method for the concentration of plasma and recovery of fractions thereof that... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080009447 - Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal: The present invention relates generally to a method for the treatment and/or prophylaxis of conditions arising from or otherwise associated with aberrations in hormone signaling. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of conditions, the amelioration of symptoms of which, are facilitated by an... Agent: Leopold Presser Scully, Scott, Murphy & Presser

20080009441 - Polypeptide inducing the secretion of angiopoietin: This invention relates to Cell supernatant protein for inducing angiogenesis-1 secretion. The protein of the invention can be useful as therapeutic agent for angiogenesis-related diseases.... Agent: Baker & Daniels LLP

20080009446 - Recombinant human albumin fusion proteins with long-lasting biological effects: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and... Agent: Yi Li

20080009438 - Screening methods for compounds useful in the regulation of body weight: The present invention relates to drug screening assays, and diagnostic and therapeutic methods for the treatment of body weight disorders, such as obesity, anorexia and cachexia, utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention. The invention also relates to compounds that modulate the activity or expression of the... Agent: Millennium Pharmaceuticals, Inc.

20080009442 - Therapeutic use for alpha1 proteinase inhibitor in hematopoiesis: A previously unrecognized fundamental property of α1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified α1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or... Agent: Darby & Darby P.C.

20080009448 - Peptide derivative: A pharmaceutical composition comprising a peptide derivative or its pharmaceutical equivalent salt having a general formula, R1N═C(R2)-AA1-AA2-AA3-AA4-Y, in which R1 is such as a hydrogen, R2 is such as a methyl group, Y is such as a methylamino group, AA1 is such as a tyrosine group, AA2 is such as... Agent: Lackenbach Siegel, LLP

20080009450 - Genipin derivatives and uses thereof: Genipin derivatives and pharmaceutical compositions thereof that inhibit the activity of uncoupling protein-2 (UCP2) and are useful in treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia in a mammal are disclosed.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080009451 - Applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor: The present invention provides a method to diagnose the kidney function of secreating kidney secreted bone growth factor (KSBGF) by examining the blood concentration of KSBGF, a method to diagnose the state of bone formation by examining the blood concentration of KSBGF, a method to produce KSBGF, a method of... Agent: Mian Long

20080009452 - Pesticidal composition: The present invention provides an insecticidal composition comprising of at least one insecticidal compound with effective knock-down action selected from among group (A) comprising of imidacloprid, acetamiprid, thiamethoxam, thiacloprid, nitenpyram, dinotefuran, clothianidin, abamectin, emamectin, emamectin benzoate and fipronil, and at least one insecticidal compound with effective long-term action selected from... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080009456 - Antisense modulation of kinesin-like 1 expression: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like... Agent: Knobbe, Martens, Olson & Bear, LLP

20080009457 - Cochleate compositions directed against expression of proteins: Disclosed herein are novel siRNA-cochleate and morpholino-cochleate compositions. Also disclosed are methods of making and using siRNA-cochleate and morpholino-cochleate compositions.... Agent: Lahive & Cockfield, LLP

20080009458 - Cop1 molecules and uses thereof: The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding.... Agent: Heller Ehrman LLP

20080009455 - Immunostimulatory oligonucleotides: The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.... Agent: Wolf Greenfield & Sacks, P.C.

20080009459 - Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences: The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunstimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection.... Agent: Morrison & Foerster LLP

20080009460 - Method to treat sickle cell disease: The present invention provides a therapeutic method for treating an inflammatory response caused by a sickle cell crisis, comprising administration of an effective amount amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor (e.g., rolipram).... Agent: Schwegman, Lundberg & Woessner, P.A.

20080009461 - Therapeutic compounds: The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2′-methoxy adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs of adenosine receptor agonists, and to their use as therapeutic compounds,... Agent: Edwards Angell Palmer & Dodge LLP

20080009462 - Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates: The present invention relates to phosphonate, nucleoside phosphonate or nucleoside phosphate compounds, compositions containing them, processes for obtaining them, and their use in treating a variety of medical disorders, in particular viral infections, cancers and the like.... Agent: Swanson & Bratschun, L.L.C.

20080009463 - Method of treating dry eye disease with purinergic receptor agonists: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5′-triphosphate (UTP), dinucleotides, cytidine 5′-triphosphate (CTP), adenosine 5′-triphosphate (ATP), or their therapeutically... Agent: Howery LLP

20080009464 - Boronated metal-phthalocyanines, process for their preparation, pharmaceutical compositions comprising them and use thereof: The present invention relates to meta 1-phthalocyanines bearing at least a group containing boron isotopes 11B or 10B, covalently bound to the peripheral positions of meta 1-phthalocyanine nucleus; moreover it refers to the processes for their preparation, the pharmaceutical compositions comprising them and their use for the treatment of neoplastic... Agent: Wolf Greenfield & Sacks, P.C.

20080009466 - Crystalline forms of ibandronic acid and processes for preparation thereof: The invention relates to solid crystalline forms of ibandronic acid, pharmaceutical formulations thereof, and methods of treatment therewith.... Agent: Kenyon & Kenyon LLP

20080009467 - Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism: Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, mild cognitive impairment, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between... Agent: Swanson & Bratschun, L.L.C.

20080009468 - Method for reducing psa levels: A method for reducing an antigen indicator of prostate cancer and for reducing the need for biopsies in men suspected of having prostate cancer and a method for treating patients with elevated PSA levels. In one method, the level of an antigen indicator of prostate cancer is measured and for... Agent: Norris, Mclaughlin & Marcus, Pa

20080009469 - Medicament for threapeutic treating of pain: A medicament for therapeutic and/or prophylactic treatment of pain such as neuropathic pain that occurs after peripheral or central nerve injury, which contains ginsenoside Rb1 as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20080009470 - Acremonic acid derivatives: m

20080009471 - Ocular delivery of triamcinolone acetonide phosphate and related compounds: The present invention provides systems and methods for ocularly delivering a triamcinolone acetonide agent to a subject. In one aspect, for example, a method is provided for treating or preventing an ocular condition in a subject for which triamcinolone acetonide is effective. Such a method may include ocularly administering a... Agent: Thorpe North & Western, LLP.

20080009472 - Prostate cancer treatment: The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it... Agent: Hollis-eden Pharmaceuticals, Inc.

20080009473 - Pyridyl-substituted porphyrin compounds and methods of use thereof: The present invention relates to Pyridyl-Substituted Porphyrin Compounds, compositions comprising an effective amount of a Pyridyl-Substituted Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction due to surgery, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an inflammatory... Agent: Wilmerhale/new York

20080009474 - Penem prodrugs: e

20080009475 - Pharmacological treatment of cognitive impairment: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.... Agent: Bozicevic, Field & Francis LLP

20080009476 - Treating conjunctivitis by topically administering an epinastine solution to the conjunctiva: Treating allergic conjunctivitis by administered aqueous solutions containing epinastine, optionally in the form of its racemate or its enantiomers and optionally, in the form of the pharmacologically acceptable acid addition salts thereof, to the conjunctiva.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080009477 - Arylalkyl ureas as cb1 antagonists: CB1 antagonists are provided. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 receptor modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and... Agent: Neurogen Corporation

20080009478 - Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases: The present invention relates to substituted-2,3,4,5-tetrahydro-3-benzazepine derivatives that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2C receptor associated diseases, conditions or disorders, such as, obesity and related disorders.... Agent: Fish & Richardson P.C.

20080009479 - Tetrahydrobenzazepines as histamine h3 receptor ligands: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080009480 - Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives: R6 and R7 are each independently hydrogen, C1-C6 alkyl or cycloalkyl; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions containing these compounds and methods for their use, including treatment of obsessive-compulsive disorder, panic disorder, depression, anxiety, generalized anxiety disorder, schizophrenia, migraine, sleep disorders, eating disorders, obesity, epilepsy,... Agent: Fitzpatrick Cella Harper & Scinto

20080009481 - Process for making form i of olanzapine: This invention discloses a new dihydrate polymorph of Olanzapine (hereinafter referred to as “dihydrate C”), and process for recovering anhydrous Form I of Olanzapine from this novel Dihydrate C.... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20080009482 - Novel compounds: i

20080009483 - Antibacterial agents: Napthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080009484 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents: The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080009485 - Methods for the use of inhibitors of cytosolic phospholipase a2 in the treatment of thrombosis: e

20080009486 - Spiroindolinone derivatives:

20080009487 - Treatment of athersclerotic disease: The invention features a method of inhibiting the progression of intima-media thickening, or reducing the intima-media thickness (IMT) in arteries in a patient in need thereof by administering to the patient a rifamycin in an amount effective to inhibit the progression of intima-media thickening, or reduce the IMT. The invention... Agent: Clark & Elbing LLP

20080009488 - Raf modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080009489 - Androgen receptor modulators and method of treating disease using the same: Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.... Agent: Wilson Sonsini Goodrich & Rosati

20080009490 - Hiv integrase inhibitors: wherein a, b, Y, R1, R2, R3 and R4 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se... Agent: Merck And Co., Inc

20080009491 - Pyridoimidazole derivatives: The present invention relates to pyridoimidazole derivatives that act as cannabinoid receptor ligands, e.g., CB2 ligands. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Att: Michael Ciraolo

20080009492 - Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents: e

20080009493 - Substituted benzimidazoles and imidazo-[4,5]-pyridines: 2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.... Agent: Philip S. Johnson Johnson & Johnson

20080009495 - Compound containing basic group and use thereof: wherein symbols in formula have the same meanings as described in the present specification, a salt thereof, an N-oxide thereof or a solvate thereof or a prodrug thereof, and medical use thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a... Agent: Sughrue-265550

20080009494 - Cycloalkyl substituted pyrimidinediamine compounds and their uses: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080009496 - Mutagenic heterocycles: The present invention provides compounds as well as methods of using the compounds as antiviral and anti-cancer chemotherapeutic agents.... Agent: Townsend And Townsend And Crew, LLP

20080009497 - Pyrrolotriazine kinase inhibitors: e

20080009498 - Phosphodiesterase inhibitors and nitric oxide donors, compositions and methods of use: The invention provides novel compositions containing at least one phosphodiesterase inhibitor, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents.... Agent: Wilmerhale/nitromed

20080009499 - Alkyl-pyridazine derivatives as 11b-hsd1 inhibitors: e

20080009500 - Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders: The invention provides α-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein α-mimetic compounds are used to treat fibrotic disorders.... Agent: Davis Wright Tremaine, LLP/seattle

20080009501 - Methods for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments: A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a methotrexate based medicament, wherein the methotrexate based medicament... Agent: Factor & Lake, Ltd

20080009502 - Tadalafil solid composites: This invention relates to oral pharmaceutical compositions suitable for making pharmaceutical formulations for oral administration that provide for the rapid dissolution of the phosphodiesterase 5 inhibitor tadalafil. In particular, the pharmaceutical compositions comprise solid composites of tadalafil exhibiting high solubility and rate of dissolution. The invention further relates to methods... Agent: Kenyon & Kenyon LLP

20080009503 - Method of treating diabetes: Methods are provided for lowering plasma level of HbA1c in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease and slowing or delaying the development of or worsening of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient.... Agent: Cv Therapeutics, Inc.

20080009504 - Antifungal agents: The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-β-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080009505 - Theanine derivatives, uses thereof and processes for the manufacture thereof: The present invention provides compounds, including peptides, which comprise theanine and/or theanine-like moieties. These compounds may deliver the physiological effects of theanine and/or offer enhanced storage stability. Also provided is a process for manufacturing the compounds by reacting theanine or a derivative thereof with at least one amino acid or... Agent: Unilever Intellectual Property Group

20080009506 - Imidazole compound: e

20080009507 - Inhibitors of akt activity: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of... Agent: Merck And Co., Inc

20080009508 - 6,9-disubstituted purine derivatives and their use for treating skin: The present invention provides methods and compositions for countering the adverse effects of aging on mammalian cells in vitro and in vivo, especially human skin cells and human skin, and treatment of hyperproliferative and related skin diseases in mammals by administering compositions containing 6,9-disubstituted purine derivatives.... Agent: Fitch Even Tabin And Flannery

20080009509 - Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof: The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof for inhibiting the growth of cancer cells, a method for the preparation thereof and a pharmaceutical composition comprising same as an active ingredient.... Agent: Sughrue Mion, PLLC

20080009510 - Fused aminopiperidine as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is... Agent: Merck And Co., Inc

20080009511 - Cancer treatment with compounds inhibiting pkc alpha: A chemotherapeutic cancer treatment with Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425, Ro31-8220, Ro31-0432 and NGIC-1 or chemical compounds with similar structures is administered to a mammal for the treatment of the cancer. The chemical compound is targeted to PKC α activity. Experiments indicate that Gö7874, Gö6850, Gö7612, Gö7852, Ro31-7549, Ro31-8425,... Agent: Robert E. Bushnell

20080009514 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition: wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080009512 - Tetrahydroquinolones and aza-analogues thereof for use as dpp-iv inhibitors in the treatment of diabetes: Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R1 is selected from: formula a) or b) (wherein is a single or double bond); R5, R6, R7 and R8 are for or alkyl; R4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted... Agent: Astrazeneca R&d Boston

20080009513 - Therapeutic agents: The present invention relates to 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula IA and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.... Agent: Morgan Lewis & Bockius LLP

20080009515 - Substituted thieno[3,2-c]pyridine carboxylic acid derivatives: e

20080009516 - Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase: Provided is a method of increasing the stability of wild-type β-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a... Agent: Baker Botts L.L.P.

20080009517 - Use of nelfinavir as a radiation sensitizer: The present invention relates to the sensitization of a cell to radiation. In particular, the present invention relates to the use of a protease inhibitor to sensitize a cancer cell to radiation.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080009518 - 5-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists: The present invention is directed to certain 5-phenyl-5,6,7,8-hydroquinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20080009519 - Method of modulating t cell functioning: A method of modulating TH1 cell functioning in a mammal, comprising administering to said mammal an effective amount of one or more IDO-mediated tryptophan metabolites or derivatives thereof; or an antagonist thereof.... Agent: Bozicevic, Field & Francis LLP

20080009520 - Benzimidazolidinone derivatives as muscarinic agents: Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20080009521 - Aryl piperidine amides: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.... Agent: Philip S. Johnson Johnson & Johnson

20080009522 - Biphenylcarboxamides useful as lipid lowering agents: e

20080009523 - New pyridine analogues iv:

20080009524 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O'brien

20080009525 - Activator of peroxisome proliferator-activated receptor delta: (wherein R1 represents phenyl, etc. which can have substituents selected from the group consisting of C1-8 alkyl, C1-8 alkyl having halogen, halogen, hydroxyl, etc.; R2 represents C1-8 alkyl, etc.; A represents oxygen, sulfur, etc.; X represents C1-8 alkylene chain, etc.; Y represents C(═O), CH═CH, etc.; R3, R4, and R5 each... Agent: Jones Day

20080009526 - Liquid termiticide compositions of pyrethroids and neonicitinoids: The present invention relates to liquid termiticide compositions comprising a pyrethroid and a neonicotinoid selected from the group consisting of imidacloprid, nithiazine, thiamethoxam, dinotefuran, nitenpyram, thiacloprid and clothianadin, these compositions result in an increase in termite mortality at low application rates and a continuous chemical barrier of a termiticide in... Agent: Patent Administrator Fmc Corporation

20080009527 - Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se,... Agent: Millen, White, Zelano & Branigan, P.C.

20080009528 - Antibacterial agents and related screening methods using small molecule macroarrays: The present invention relates generally to compounds providing antibacterial therapeutic agents and preparations, and related methods of using and making antibacterial compounds. Antibacterial compounds of the present invention include chalcone, alkylpyrimidine, aminopyrimidine and cyanopyridine compounds and derivatives thereof exhibiting minimum inhibitory concentrations (MIC) similar to or less than conventional antibacterial... Agent: Greenlee Winner And Sullivan P C

20080009529 - Methods and compositions for controlling algae: Described are preferred methods and compositions for controlling algae which involve the use of bleaching pyridinecarboxamide compounds.... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20080009530 - Therapeutic agent for diabetes: The present invention provides an agent for the prophylaxis or treatment of diabetes, which is associated with a ferwer side effects such as body weight gain, adipocyte accumulation, cardiac hypertrophy and the like, and which contains a compound represented by the formula: wherein each symbol is as defined in the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080009531 - 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes: The present invention relates to 5-anilino-4-heteroarylpyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.... Agent: Jeffrey M. Greenman

20080009532 - Antimicrobially finished solid preparations: The antimicrobially finished aqueous preparations of water-insoluble solids comprising 1,2-benzisothiazolin-3-one (BIT) and at least one further biocidally active compound are distinguished by rapid onset of action with good long-term action (even at low concentration of the biocide mixtures used) and good environmental compatibility.... Agent: Lanxess Corporation

20080009533 - Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method: e

20080009534 - Substituted acid derivatives useful as antidiabetic and antiobesity agents and method:

20080009535 - Inhibitors of phosphodiesterase type-iv: The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080009536 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially... Agent: Morrison & Foerster LLP

20080009537 - Therapeutic agent for diabetes comprising protease-inhibiting compound: t

20080009538 - Methods and compositions for the treatment of urinary incontinence: Methods and compositions containing bicifadine are provided for the prevention and treatment of lower urinary tract disorders in mammalian subjects. The methods and compositions may be used to prevent or treat urinary incontinence, urinary urgency, nocturia, and enuresis associated with neurogenic and non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostadynia, and... Agent: Black Lowe & Graham PLLC

20080009539 - Azo compounds and process for production thereof: [wherein R1 and R2 are each independently C1-6 alkyl; R3 is optionally substituted aryl; and R4, R5 and R6 are each independently hydrogen, C1-6 alkyl, halogeno, C1-6 alkoxy, or C1-6 alkylthio] with a benzenediazonium salt having an electron-withdrawing group at the p- and/or o-position in a mixed solvent composed of... Agent: Foley And Lardner LLP Suite 500

20080009540 - Amorphous atorvastatin calcium: Amorphous atorvastatin calcium having an enhanced stability contains about 2 to about 8 percent by weight water. A process for preparing the amorphous atorvastatin calcium and a packaging system for maintaining the stability are described.... Agent: Dr. Reddy's Laboratories, Inc.

20080009541 - Novel receptor antagonists and their methods of use: o

20080009542 - Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy) phenoxathiin-10,10-dioxide: Provided herein is a new form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide, which demonstrates higher stability relative to other forms of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide. In particular, this new form affords less dosage critical administration of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin 10,10-dioxide relative to other forms. The new solid form of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide has been determined and is provided herein. This... Agent: Knobbe Martens Olson & Bear LLP

20080009543 - N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application: o

20080009544 - Pharmaceutical composition useful as acetylcholinesterase inhibitors: A pharmaceutical composition useful as acetylcholinesterase inhibitors. The present invention relates to pharmaceutical composition comprising the naturally occurring compounds selected from (±) Marmesin, Columbianetin, Dihydroxanthyletin and substituted coumarin derivatives of 7-allyloxy coumarin, 7-benzyloxy coumarin, 7-methoxy coumarin, 7-acetyloxy coumarin, 4-methyl-7-hydroxy coumarin and 4-methyl-7-acetyloxy coumarin. The said compositions posses a high degree... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080009545 - Anticancer agents: wherein X is selected from oxygen, nitrogen and sulfur; n is 0 or 1; R1 is selected from alkyl, carboxylic acid, carboxylate, carboxamide, ester and combinations thereof; R2 is selected from alkyl, substituted alkyl, carboxylic acid, carboxylate, carboxamide, sulfonyl, sulfonamide and combinations thereof; and derivatives and metabolites thereof. Further provided... Agent: Calfee Halter & Griswold, LLP

20080009546 - Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders: This invention relates to diamondoid derivatives which exhibit therapeutic activity. Specifically, the diamondoid derivatives herein exhibit therapeutic effects in the treatment of neurologic disorders. Also provided are methods of treatment, prevention and inhibition of neurologic disorders in a subject in need.... Agent: Buchanan, Ingersoll & Rooney PC

20080009547 - Method for inhibiting or reversing non-enzymatic glycation: The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an α-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.... Agent: Licata & Tyrrell P.C.

20080009548 - Ambroxol for the treatment of acute pain: A method of treating acute pain in a patient in need thereof, the method comprising orally administering to the patient ambroxol or a pharmacologically acceptable salt thereof.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080009549 - Composition for sterilization comprising w-alkoxyperoxycarboxylic acid: (wherein R1 represents a substituted or unsubstituted C1-C10 alkyl group, or a substituted or unsubstituted C6-C10 aryl group, L represents a substituted or unsubstituted C2-C12 divalent linking group, or R1 and L may combine to form a ring) and a composition comprising said peroxycarboxylic acid are provided. Said peroxycarboxylic acid... Agent: Sughrue Mion, PLLC

20080009550 - Stabilized body care products, household products, textiles and fabrics: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain dialkylhydroxyamine stabilizers, dialkylhydroxylamine stabilizer salts, nitrone stabilizers or amine oxide stabilizers. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric... Agent: Ciba Specialty Chemicals Corporation Patent Department

20080009551 - Methods and compositions for identifying modulators of g protein-coupled receptors: The subject invention provides methods for making ligand upregulatable G-protein coupled receptors (GPCRs). Ligand upregulatable GPCRs contain a modified TM5-IC3-TM6 segment, which provides for increased levels of the ligand upregulatable GPCR in a host cell in the presence of a ligand as compared to the absence of the ligand. The... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20080009552 - Markers of pre-term labor: The invention relates to novel markers of pre-term labor, methods for assessing the status of pre-term labor using the markers, and methods for the diagnosis and therapy of pre-term labor.... Agent: Mccarthy Tetrault LLP

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.46462 seconds

PATENT INFO